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MUTANT P53 IN PRE-LEUKEMIC HEMATOPOIETIC STEM CELLS AND THE 
PATHOGENESIS OF MYELODYSPLASTIC SYNDROME 
 
          Myelodysplastic syndrome (MDS) is a clonal disease arising from mutated 
hematopoietic stem cells (HSCs). MDS stem cells originate from pre-leukemic 
HSCs, which have enhanced competitive advantage over wild-type (WT) HSCs 
but normal differentiation capacity. Recently, acquired somatic gain-of-function 
(GOF) TP53 mutations were identified in the blood of aged healthy individuals as 
well as in patients with MDS. However, the role of GOF TP53 mutations in clonal 
hematopoiesis and the pathogenesis of MDS is largely unknown. 
          Based upon our previous studies and clinical findings, I hypothesized that 
GOF mutant p53 drives the development of pre-leukemic HSCs with enhanced 
competitive advantage, leading to clonal expansion and the pathogenesis of 
MDS. To test my hypothesis, I examined HSC behaviors in young p53+/+ and 
p53R248W/+ mice. I discovered that p53R248W enhances the repopulating potential 
of HSCs without affecting terminal differentiation. I also found that GOF mutant 
p53 protects HSCs from genotoxic stress and promotes their expansion. To 
investigate the role of mutant p53 in the pathogenesis of hematological 
malignancies, I monitored disease development in p53+/+ and p53R248W/+ mice 
and observed that some mutant p53 mice develop MDS during aging. Therefore, 
I demonstrated that GOF mutant p53 enhances the repopulating potential of 
vi 
HSCs and drives the development of pre-leukemic HSCs, predisposing aged 
mutant p53 mice to MDS development. 
          Mechanistically, I found that mutant p53 increases the chromatin 
accessibility to genes important for HSC maintenance, including pluripotent gene 
Sox2 and chemokine gene Cxcl9. By performing biochemical experiments, I 
discovered that GOF mutant p53, but not WT p53, interacts with histone 
methyltransferase EZH2 and enhances histone H3 lysine 27 trimethylation 
(H3K27me3) at genes, including Mef/Elf4 and Gadd45g, that negatively regulate 
HSC self-renewal.  
          Collectively, these findings demonstrated that GOF mutant p53 drives pre-
leukemic HSC development through modulating epigenetic pathways. Thus, our 
studies have uncovered novel mechanistic and functional links between GOF 
mutant p53 and epigenetic regulators in pre-leukemic HSCs. This research may 
identify epigenetic regulator EZH2 as a novel target for the prevention and 
treatment of MDS patients with TP53 mutations.  
 
Yan Liu, Ph.D. 
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1 
CHAPTER ONE 
Introduction 
Hematopoiesis 
1. Hematopoietic hierarchy 
Hematopoiesis is the process of blood cell production in an organism. It is 
initiated by a rare population of hematopoietic stem cells (HSCs) residing in the 
bone marrow (Kondo, et al., 2003; Attar et al., 2004). The frequency of HSCs is 
less than 0.01% of total bone marrow cells (Orkin, 2008; Zon, 2008). HSCs are 
the only population within the hematopoietic compartment that can self-renewal 
life-long and undergo multi-lineage differentiation to produce all types of mature 
blood cells (Akala et al., 2006, Zon, 2008). The majority of HSCs are in the 
quiescent state in order to maintain the integrity and function of HSC pool. In 
order to replenish blood system and maintain HSC pool throughout the life of an 
organism, HSCs have to keep the balance of self-renewal and differentiation 
(Orkin, 2008; Zon, 2008; Walasek et al., 2012). Disruption of the balance may 
cause blood disorders, such as anemia, bone marrow failure, and leukemia. 
Hematopoiesis has a hierarchical structure and HSCs are at the top of the 
hierarchy as illustrated in Figure 1.1 (Wang et al., 2011). HSCs can be divided 
into long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs). LT-HSCs 
have unlimited self-renewal potential, whereas the self-renewal potential ST-
HSCs is limited. ST-HSCs tend to enter the cell cycle and give rise to  
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Figure 1.1 Hematopoietic hierarchy in adult bone marrow. 
(Adapted from Wang et al., 2011) 
3 
multi-potent progenitor cells (MPPs), which then generate several types of 
lineage-committed progenitors, including common myeloid progenitors (CMPs), 
megakaryocyte-erythrocyte progenitors (MEPs), granulocyte-macrophage 
progenitors (GMPs) and common lymphocyte progenitors (CLPs). These lineage-
committed progenitors have excessive proliferating capability and eventually 
differentiate into all mature blood cells, such including erythrocytes, neutrophils, 
macrophage, platelet, granulocyte, B cells and T cells. Diverse mature blood 
cells have distinct functions that sustain the life of an organism. For example, red 
blood cells (RBCs) carry oxygen and remove carbon dioxide, B cells and T cells 
build adaptive immune system, and platelets involve in clotting to stop bleeding. 
2. Hematopoietic cell identification 
Different subsets of hematopoietic stem and progenitor cell populations 
can be functionally and immuno-phenotypically identified. Functional LT-HSCs 
can be determined by in vivo transplantation experiments. LT-HSCs can mediate 
multi-lineage reconstitution in lethally irradiated recipient mice for at least 4 
months, and these HSCs can serially repopulate the blood systems in secondary 
transplantation and even tertiary transplantation assays (Akala et al., 2006; 
Orkin, 2008; Zon, 2008).  However, multipotent progenitor cells can only 
contribute to hematopoietic reconstitution for up to 3 months. Hence, serial bone 
marrow transplantation assay is the gold standard for examining LT-HSC 
function and self-renewal capacity.  
HSCs can be purified from the bone marrow immuno-phenotypically by 
using cell surface markers and flow cytometry analysis. In the murine blood 
4 
system, mature blood cells express distinct surface markers, including B220, 
CD3e, CD11b, Gr1, and Ter119, shown in Table 1. However, hematopoietic stem 
and progenitor cells do not express these lineage cell surface markers and 
therefore designated as lineage negative (Lin-) cells. In the past two decades, 
significant progress has been made to isolate the most primitive murine 
hematopoietic stem cells. For example, stem cell factor (SCF) receptor c-Kit was 
identified in 1990s to be exclusively expressed in mouse hematopoietic 
progenitor cells that have multi-lineage reconstitution capability (Ogawa et al., 
1991). Lin-Sca1+c-Kit+ (LSKs) are still heterogeneous and only 4% LSKs are 
functional HSCs (Morrison et al., 1994; Challen et al., 2009). The identification of 
the signaling lymphocytic activation molecule (SLAM) family proteins has led to 
further enrichment of more primitive HSCs (Kiel et al., 2005; Challen et al., 2009). 
LSKs can be separated into several functionally distinct sub-populations by using 
the SLAM markers. LT-HSCs highly express the SLAM marker CD150, but not 
CD48. The expression of CD48 increases as HSCs differentiate into less 
primitive populations, including ST-HSCs and MPPs. LT-HSCs can be purified as 
Lin-Sca1+c-Kit+CD48-CD150+ cells from the bone marrow (Challen et al., 2009). 
In this study, I utilized the SLAM surface markers to isolate LT-HSCs as shown in 
Table 1. 
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Hematopoietic Populations Surface Marker 
Long-term hematopoietic stem cells 
(LT-HSC) Lin
-Sca1+c-Kit+CD48-CD150+ 
Short-term hematopoietic stem cells 
(ST-HSC) Lin
-Sca1+c-Kit+CD48-CD150+ 
Multipotent progenitors (MPP) Lin-Sca1+c-Kit+CD48+CD150- 
LSK Lin-Sca1+c-Kit+ 
Common lymphocyte progenitors 
(CLP) Lin
-Sca-1Lowc-KitLowIL-7Rα+ 
Common myeloid progenitors 
(CMP) Lin
−Sca1−Kit+FcγRII/IIIlowCD34high 
Granulocytic monocytic progenitors 
(GMP) Lin
−Sca1−Kit+FcγRII/IIIhighCD34high 
Megakaryocyte erythroid progenitors 
(MEP) Lin
−Sca1−Kit+FcγRII/IIIlowCD34low 
Granulocytes and monocytes Gr1+Mac1+ 
B cells B220+ 
T cells CD3+ 
Erythroid cells Ter119+ 
Table 1.1 Cell surface markers for hematopoietic populations 
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3. Molecular mechanisms controlling adult hematopoietic stem cell fate 
Elucidating the molecular mechanisms underlying HSC fate determination 
has been a focus of HSC research. Adult HSCs mainly reside within the bone 
marrow, which consists of various hematopoietic and non-hematopoietic cells. 
The complexity of the bone marrow microenvironment indicate that HSC fate 
may be controlled by both stem cell intrinsic factors and extrinsic factors (Akala 
et al., 2006, Zon, 2008; Wang et al., 2011). 
The regulation of HSC behavior demands a complex crosstalk between 
the stem cell-intrinsic regulators and extrinsic regulatory signals from the 
microenvironment, illustrated in Figure 1.2 (Zon 2008). In this session, I will 
briefly describe how HSC functions are tightly regulated by transcription factors 
and epigenetic regulators in a cell-autonomous manner. 
 
 
 
 
 
 
 
 
 
 
 
7 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Molecular mechanisms involved in adult HSC self-
renewal and differentiation.  
(Adapted from Zon, 2008) 
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3.1 Transcription factors 
A large number of transcription factors play essential roles in controlling 
HSC fates. For example, the cluster of Hox proteins, an evolutionary conserved 
family of proteins by a DNA-binding motif, have been implicated in the regulation 
of HSCs as well as leukemogenesis. Enforced expression or silencing of certain 
Hox genes in mouse model or human blood cells has delineated their impacts on 
hematopoiesis. Overexpression of Hoxb4 in bone marrow cells promotes 
expansion of HSC populations in vivo and ex vivo, enhancing HSC stemness 
without affecting normal bone marrow development (Sauvageau, et al., 1995). 
Ectopic Hoxa10 expression increases HSC self-renewal but impairs 
megakaryocyte and erythroid cell differentiation (Magnusson et al., 2007). By 
contrast, overexpression of Hoxa9 promotes myeloid differentiation and leukemia 
development (Thorsteinsdottir et al., 2002).  
Members of the ETS (‘E twenty-six’) family of transcription factors govern 
the gene regulatory networks important for hematopoiesis (Ciau-Uitz et al., 
2013). While all ETS transcription factors share similar binding motif, their 
functions are context-dependent and each ETS transcription factor plays distinct 
roles in different contexts. For instance, PU.1 is one of the most important ETS 
family proteins in hematopoiesis, playing indispensable roles supporting HSC 
commitment (Will et al., 2015). Its expression is low in HSCs but increases as 
HSCs undergo lineage commitment. Recently, findings by Steidl and colleagues 
suggested that reduction of PU.1 at 35% promotes the development of pre-
leukemic HSCs and subsequently leads to leukemic transformation (Will et al., 
9 
2015). MEF, also known as ELF4, is another a key ETS factor in regulating HSC 
quiescence (Lacorazza et al., 2006). Mef null HSCs are more quiescent and thus 
are resistant to chemotherapy or irradiation treatment (Lacorazza et al., 2006). 
ERG maintains HSC self-renewal during stress hematopoiesis and regulates 
megakaryopoiesis in steady state (Min et al., 2008). The ETS transcription factor 
ETV7 forces quiescent HSCs to enter the cell cycle and exhausts HSCs by 
promoting proliferation (Geltink et al., 2013). 
3.2 Epigenetic modifications 
Epigenetic modifications, including histone modifications and DNA 
methylation, impact important biological processes through modulating unique 
gene expression patterns in a context-dependent manner (Beerman et al., 2015). 
Epigenetic modulations play essential roles at different stages of HSC 
development and stem cell fate determinations (Goldberg et al., 2007; 
Buenrostro et al., 2013; Sun et al., 2014). Here, I will use Polycomb group (PcG) 
proteins as examples to illustrate this aspect.  
3.3 Polycomb Repressive Complex 
The PcG proteins are epigenetic gene silencers that have been implicated 
in stem cell maintenance and cancer development (Bernstein et al., 2006; 
Goldberg et al., 2007; Bracken et al., 2009; Margueron et al., 2011). Genetic and 
biochemical studies indicate that Polycomb group proteins exist in at least two 
protein complexes, Polycomb repressive complex 2 (PRC2) and Polycomb 
repressive complex 1 (PRC1), that work in concert to initiate and maintain stable 
gene repression (Bernstein et al., 2006; Bracken et al., 2009). In stem cells, the 
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PcG proteins repress the transcription of lineage-specific differentiation genes to 
maintain stemness. In response to differentiation signals, the PcG proteins are 
displaced from lineage-specific genes and recruited to stem cell-specific genes to 
facilitate differentiation (Bernstein et al., 2006; Xie et al., 2014b). 
Bmi1 is a critical component of the PRC1 complex in hematopoiesis. Loss 
of Bmi1 impairs HSC self-renewal and blocks terminal differentiation, whereas 
forced expression of Bmi1 in HSCs promotes HSC self-renewal by repressing 
cell-cycle regulator p16INK4A and p19ARF, resulting in symmetrical stem cell 
division (Molofsky et al., 2003; Park et al., 2003; Gao et al., 2012). The self-
renewal defect of Bmi1-/- mice can be rescued by elimination of both p16 and p19 
(Iwama et al., 2004). We have been studying the role of Bmi1 in HSC self-
renewal and terminal differentiation. We reported that AKT-mediated 
phosphorylation of Bmi1 impairs its function in HSC self-renewal (Liu et al., 
2012), implicating that phosphorylation of Bmi1 can act as a therapeutic strategy 
to eliminate cancer stem cells. Additionally, we discovered that Bmi1 promotes 
erythroid development partially through regulating ribosome biogenesis and that 
Bmi1 deficiency may cause diamond blackfan anemia (DBA) (Gao et al., 2014).  
3.4 Enhancer of Zeste Homologue 2 
EZH2, Enhancer of Zeste Homologue 2, is a methyltransferase. It is a 
catalytically active component of the PRC2 complex. EZH2 represses gene 
expression through di- and tri-methylations lysine 27 of histone H3 (H3K27me2 
or H3K27me3) (Margueron et al., 2011; Xie et al., 2014b). Overexpression of 
EZH2 enhances HSC maintenance, whereas loss of EZH2 decreases the 
11 
engraftment of HSCs in repopulation assays (Kamminga et al., 2006; Mochizuki-
Kashio et al., 2017). Meanwhile, EZH2 controls normal B cell differentiation (Xie 
et al., 2014b). These findings suggest that EZH2 regulates both HSC self-
renewal and differentiation. Remarkably, gain-of-function EZH2 mutations, have 
been discovered in many hematological malignancies, like lymphoma, acute 
myeloid leukemia and multiple myeloma (Shih et al., 2012). Pharmacological 
inhibition of EZH2 inhibits HSC self-renewal (Campbell et al., 2015), therefore 
providing a potentially therapeutic strategy to treat patients with high activity of 
EHZ2. On the other hand, EZH2 loss-of-function mutations also exist to promote 
myeloid progenitor self-renewal reprogram through inducing HOXA9 expression 
(Margueron et al., 2011; Xie et al., 2014b). These findings suggest a dual role of 
EZH2 as tumor suppressor or onco-protein in a context-dependent manner.       
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Pre-leukemic hematopoietic stem cells  
Acute myeloid leukemia (AML) is an aggressive hematological malignancy 
in which mutated hematopoietic stem and progenitor cells give rise to clonal blast 
cells without normal differentiation (Sykes et al., 2015). Previously, it was 
believed that HSCs acquiring driving mutations will directly transformed to 
disease initiating cells, so called leukemic stem cells (LSC) (Majeti, 2014; Sykes 
et al., 2015). However, this concept was challenged by next-generation 
sequencing of genetic mutations in AML patients. Dr. Dick’s and Dr. Majeti’s 
groups recently reported that some recurrent mutations in AML, such as 
DNMT3A mutations, are pre-leukemic mutations (Corces-Zimmerman et al., 
2014; Shlush et al., 2014). Most of them are recurrent mutated in genes involved 
in epigenetic modifications.  
Based on their work, people started to appreciate that the transformation 
of disease initiating cells follows a stepwise manner of acquisition of mutations or 
epigenetic changes in HSCs. As illustrated in Figure 1.3 (Corces-Zimmerman et 
al., 2014), HSCs first acquire pre-leukemic mutations and give rise to pre-
leukemic HSC. These pre-leukemic mutations confer HSCs with competitive 
growth advantage, allowing clonal expansion. Pre-leukemic stage may have long 
latency and achieve clonal dominance over time. Subsequently, when acquiring 
additional mutations, chromosome aberrations or epigenetic changes, pre-
leukemic HSCs progress to fully transformed LSCs, giving rise to overt blood 
cancer (Corces-Zimmerman et al., 2014; Jan et al., 2014). According to this 
model, pre-leukemic HSCs and leukemic stem cells are functionally  
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Figure 1.3 Model of evolution of leukemia. 
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different and can be distinguished by experimental approaches. Transformed 
leukemic stem cells are defined by their capacity to initiate short-onset disease in 
irradiated murine model. By contrast, pre-leukemic HSCs show normal multi-
lineage differentiation but have competitive growth advantage over wild-type 
HSPCs in a competitive repopulation assay. 
Dick and colleagues also demonstrated that pre-leukemic HSCs are 
resistant to chemotherapy (Corces-Zimmerman et al., 2014; Shlush et al., 2014). 
The prolonged pre-leukemic phase may be shortened by genotoxic stress, such 
as radiation, X-ray and chemotherapy. Genotoxic stress causes lesions on the 
genome (Majeti, 2014; Sykes et al., 2015), resulting in introduction of secondary 
hits onto pre-leukemic background. The recognition of pre-leukemic mutations 
provide substantial understanding of why some patients with solid tumors 
developed leukemia after chemotherapy or radiation treatment. Additionally, the 
most common death of patient with AML and MDS is due to relapse (Anderson et 
al., 2011). Considering that pre-leukemic HSCs is of high risk to LSCs 
transformation under stress condition, pre-leukemic HSCs serve as a reservoir 
for relapse (Shlush et al., 2015). Therefore, targeting pre-leukemic HSCs is 
essential for the cure of blood malignancies. 
Current studies suggest that pre-leukemic state exist in many myeloid and 
lymphoid malignancies, including AML, myelodysplastic syndrome (MDS), 
chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), and etc 
(Pandolfi et al., 2013; Vasanthakumar et al., 2014). Of note, diverse diseases 
may carry a same recurrent mutation. For example, DNMT3a R882 mutation has 
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been found in AML, MDS, and juvenile myelomonocytic leukemia (JMML) 
(Vasanthakumar et al., 2014). Therefore, targeting pre-leukemic HSCs prior to 
the development of a malignancy is an attractive therapeutic strategy for cancer 
prevention. 
Pre-leukemic stage is not rare, especially in the elderly. Recent deep 
sequencing analyses have suggested that pre-leukemic somatic mutations are 
common in older people without an evidence of blood malignancies, leading to 
hematopoietic clonal expansion (Corces-Zimmerman et al., 2014; Genovese et 
al., 2014). This phenomenon is termed Clonal Hematopoiesis (CH) (Bejar et al., 
2011). The frequency of clonal somatic mutations rises with age: in 10% of 
people older than 70 years and 20% of individuals older than 90 years (Jaiswal et 
al., 2014; Jan et al., 2017). The high frequency of pre-leukemic mutations in 
healthy elder people may due to physiological stress caused by ageing, like 
chronic inflammation (Xie et al., 2014a). Notably, CH is associated with high risk 
of overt malignancies with poor prognosis. 
The most frequently mutated genes found in large populations with CH 
were epigenetic regulators, including DNMT3A, TET2, and ASXL1, which are 
also recurrently mutated in hematological malignancies (Corces-Zimmerman et 
al., 2014). Emerging studies have identified the biological impact of mutations 
in DNMT3A, TET2, and ASXL1 in HSCs and leukemic transformation (Abdel-
Wahab et al., 2012; Sato et al., 2016; Zhang et al,. 2016). Further studies are 
required to uncover the mechanism by which pre-leukemic HSCs initiate and 
transform into a fully transformed leukemic state. 
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Pathogenesis of Myelodysplastic Syndrome 
Myelodysplastic syndrome (MDS) is one of the most common 
hematological disorders related to ageing. It is a heterogeneous clonal disease 
driven by mutated HSCs (Sperling, et al., 2017; Woll, et al., 2014). According to 
the definition from The World Health Organization, MDS is characterized by 
peripheral cytopenia due to ineffective hematopoiesis, multi-lineage 
morphological dysplasia in bone marrows and peripheral blood, and the 
presence of less than 5% blast cells with high risk of progression to acute 
myeloid leukemia (AML) (Nimer, et al., 2008; Woll, et al., 2014; Sperling, et al., 
2017).  
MDS mostly occurs in the elderly. The awareness of the disease is 
improving since the aging population is increasing over time. In the United 
States, 0.005% to 0.013% of persons were diagnosed with MDS (Bejar et al., 
2014; Sperling, et al. 2017). The median age at diagnosis is about 71 to 76-year-
old (Cazzola et al., 2013). Patients with MDS have symptoms of fatigue, bleeding 
and fevers or infections, due to anemia, thrombocytopenia and neutropenia 
respectively (Lindsley et al., 2013; Sperling, et al. 2017). They often die from 
cytopenia induced complications or progression to acute myeloid leukemia. 
Identifying the cell of origin of MDS is critical to understand the 
development of the disease and find the cure for the patients. Recently, several 
groups have demonstrated that MDS is proceeded from rare mutated HSCs 
(Nimer et al., 2008; Wong et al., 2015; Sperling et al., 2017). Genetic studies of 
blood cells from large cohorts of healthy individual and MDS patients have 
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revealed that MDS results from step-wise acquisition of somatic recurrent 
mutations (Bejar et al., 2011; Kennedy et al., 2017). Clonal hematopoiesis led by 
the presence of initiating mutations in HSCs has been thought to be the first step 
in the development of clonal hematological diseases, leading to expansion of 
pre-leukemic HSCs (Bejar et al., 2011; Genovese et al., 2014; Jan et al., 2017). 
Further acquisition of cooperating mutations or chromosome aberrations in pre-
leukemic stage will eventually cause MDS or even transition to AML (Makishima 
et al., 2017; Sperling, et al. 2017). Therefore, elimination of MDS stem cells is 
likely to be essential to curing the disease. 
Recurrent mutations identified in the pathogenesis of MDS can be sorted 
into several categories according their functions, such as splicing factors, 
epigenetic regulators, tumor suppressors, cohesion complex and etc (Bejar, et 
al., 2014; Kennedy et al., 2017; Sperling et al., 2017). Genes involved in 
spliceosome components are the most frequent recurrent lesions in MDS made 
up to 60% of cases, including SF3B1, SRSF2, U2AF1 (Abdel-Wahab et al., 2011; 
Folco et al., 2011; Lee et al., 2016; Inoue et al., 2016). Interestingly, these 
mutations are heterozygous missense mutations and occur mutually exclusive, 
leading to distinct mechanisms of alteration of the splicing machinery (Yoshida et 
al., 2011; Inoue et al., 2016). SF3B1 mutations are found to be associated with 
ring sideroblasts and relatively favorable prognosis (Folco et al., 2011; Obeng et 
al., 2016; Papaemmanuil et al., 2011). Missense mutations on SRSF2 has been 
shown to alter their binding to exonic splice enhancers, leading to mis-splicing of 
EZH2 (Kim et al., 2015); whereas U2AF1 mutations enhances exon skipping 
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(Shirai et al., 2017). MDS patients with SRSF2 or U2AF1 mutations are usually 
associated with poor prognosis (Abdel-Wahab et al., 2011; Shirai et al., 2017). In 
addition, lesions in genes involved in epigenetic modifications are the second 
most common category of recurrent mutations in MDS (Bejar et al., 2011; 
Sperling et al., 2017). For example, TET2, gene involved in DNA methylation, is 
mutated in approximately 30% of MDS cases. These mutations cause 
hypermethylation of cytosines at enhancer sequences, resulting in 
downregulation of genes important for myeloid differentiation. ASXL1 alterations 
have been found in 20% of patients with MDS (Bejar et al., 2011; Sperling et al., 
2017). ASXL1 physically interacts with PRC2 and regulates H3K27me3 (Abdel-
Wahab et al., 2012). Loss of function mutations of ASXL1 leads to a decrease of 
global H3K27me3 and dysregulation of important hematopoietic genes, including 
the HOXA cluster genes, resulting in ineffective hematopoiesis (Abdel-Wahab et 
al., 2012; Abdel-Wahab et al., 2013). 
Apart from genetic mutations, cytogenetic rearrangements are also 
commonly found in patients with MDS. Importantly, acquisition of these 
abnormities during disease development is a predictor of unfavorable prognosis.  
Chromosome 5q deletions, Chromosome 7 deletions, Chromosome 17 deletions 
are one of the best understood cytogenetic aberrations in MDS (Bejar et al. 2011; 
Kennedy et al., 2017). 
Although several agents have been approved by FDA to treat MDS 
patients, such as lenalidominde, 5’-azacitidine and decitabine, the clinical 
outcome of MDS patients still remains poor (Bejar et al., 2011; Cazzola et al., 
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2013; Lindsley et al., 2013). Allogeneic bone marrow transplantation seems to be 
the most efficient treatment for MDS (Christopeit et al., 2016; Kennedy et al., 
2017; Lindsley et al., 2017), but it is far from completely cure the disease. 
Critically, some mutations, in particularly p53 alterations, are associated with 
increase relapses after allogeneic bone marrow transplantations, leading to even 
worse survival (Lindsley et al., 2017). Therefore, it is of great clinical significance 
to understand the pathogenesis of MDS and find effective therapeutic 
approaches for MDS patients.  
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p53 in hematopoiesis 
1. Role of p53 in steady state hematopoiesis 
The human TP53 gene is located on chromosome 17p and has 11 exons 
and 10 introns, encoding p53 protein. p53 was first identified as a partner protein 
of simian virus 40 (SV-40)-derived tumor antigens in 1979 (Lane et al., 1979). It 
was proposed as a proto onco-protein due to its low expression in normal cells 
and prevalent stability in transformed cells. Until decade later, p53 has been 
demonstrated as a critical tumor suppressor against cancer development (Brown 
et al., 2009). p53 proteins function as a transcription factor regulating gene 
expression and involve in different biological events depending on cell contexts 
(Khoo et al., 2014). In response to stress signals, such as oncogene activation, 
DNA damage or hypoxia, p53 is activated and trigger cell cycle arrest, DNA 
damage repair, senescence and apoptosis (Bálint et al., 2001; Brown et al., 
2009). Accordingly, p53 proteins inhibit cell proliferation, eliminate abnormal 
cells, maintain genome integrity and thereby prevent tumor development. 
In the hematopoietic system, p53 is preferentially expressed in HSC-
enriched LSK cells compared to their downstream hematopoietic progenitor cells 
(Kastan et al., 1911), implicating its important role in regulating HSC behavior. 
Indeed, emerging evidences have demonstrated that tumor suppressor p53 is a 
critical regulator of HSCs, affecting proliferation, differentiation, apoptosis and 
aging in hematopoietic system. Our group has defined a profound function of p53 
in regulating HSC quiescence through analyzing p53 knock-out mouse model. In 
the loss of p53, we observed more HSCs entering into cell cycle, suggesting that 
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p53 maintains HSC quiescence (Liu et al., 2009b). Transcript profiling assay of 
p53+/+ and p53-/- HSCs have identified Gfi-1 and Necdin as direct p53 target 
genes in regulating HSC quiescence (Liu et al., 2009b). Gfi-1 (growth factor 
independent 1) regulates HSC quiescence and maintain HSC function as Gfi-1-/- 
HSCs are more proliferative than normal HSCs (Zeng et al., 2004). Necdin is a 
growth-suppressing protein associated with myeloid leukemia (Asai et al., 2012). 
Analysis of HSCs behavior in Necdin knock-out mice indicated that Necdin 
maintains HSC quiescence in steady state and suppresses p53-dependent 
apoptosis under stress conditions.  
Cell competition is a process to select the superior (fittest cells) and 
eliminate the inferior (damaged cells). Bondar and colleagues discovered that 
p53 mediates HSPCs competition in hematopoietic system (Bondar, 2010). Cells 
with higher p53 activity were outcompeted by cells with lower p53 activity. 
Mechanistically, winner cells reprogram the loser cells and induce p53-related 
senescence phenotype to the losers (Bondar, 2010; Marusyk et al., 2010). This 
novel finding highlights the significance of p53 in hematopoietic homeostasis, 
and implicates a potential mechanism by which oncogenic mutations contribute 
to clonal expansion. Furthermore, Clarke and colleagues discovered that early 
progenitors could acquire stem-like features in the absence of Trp53, p16Ink4a and 
p19Arf, as multipotent progenitor cells from Trp53-/-p16Ink4a-/-p19Arf-/- triple 
knock-out mice achieve long-term reconstitution capacity as WT HSCs (Akala, et 
al., 2008). This study suggested a potential role of p53 in regulating self-renewal 
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of progenitor cells, implying the importance of p53 pathways in reprogramming of 
progenitor cells to self-renewal cancer stem cells. 
2. Role of p53 in stress hematopoiesis 
Stress conditions, such as irradiation, reactive oxygen species (ROS), 
chemotherapy and X-Ray, perturb hematopoiesis. The Mre11/Rad50/Nbs1 
(MRN) complex is sensor protein binding to damaged DNA. MRN complex 
activates ATM kinase and then phosphorylates p53 and other target proteins, 
leading to p53 dependent apoptosis on HSCs and progenitor cells (Mihara et al. 
2003; Brown et al., 2009; Marusyk et al., 2010). As a consequence, high dose of 
stress causes bone marrow aplasia, anemia and infections. Elimination of Bmi1 
in HSCs impairs its self-renewal capability due to the accumulation of p19Arf, 
which induces p53-dependent cell death. In contrast, inhibition of p53 activity 
results in cell resistance to the apoptosis, augmenting the effects of genotoxic 
stress (Bálint et al., 2001; Mihara et al., 2003). These further prove that p53 plays 
a pivotal role in regulating apoptosis in HSCs. 
We worked to gain a further understanding of p53 function in HSCs upon 
stress. Myeloid Elf-1-Like Factor (MEF), is a ETS Factor. We found that p53 and 
MEF double knock-out HSCs have more DNA damage indicator r-H2AX foci than 
MEF-deficient HSCs following irradiation, demonstrated that p53 promotes DNA 
damage repair in HSCs under condition of genotoxic stress (Liu et al., 2009b). 
DNA damage repair is critical for preservation of stem cell function, as it reported 
that decreased DNA damage repair activity attributed to accumulation of 
damaged DNA, resulting in reduced self-renewal capability of stem cells (Park et 
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al., 2003). Chemotherapeutic drugs trigger both p53 dependent and p53 
independent apoptosis. We reported that HSCs from p53 knock-out mice are 
more resistance to apoptosis induced by chemotherapeutic agents, and p53-null 
HSCs show enhanced repopulation potential following chemotherapy (Shounan 
et al., 1996; Park et al., 2003; Liu et al., 2009b). These studies implicated that 
activation of p53-regulated gene contributes to the death of leukemic stem cells. 
From a molecular perspective, p53 transcriptionally regulates the 
expression of pro-apoptotic genes, such as Puma, Bax and Noxa. Puma (p53 
upregulated mediator of apoptosis) induces apoptosis in HSCs under genotoxic 
stress (Brosh et al., 2009; Brown et al., 2009). Puma-null HSCs are more 
quiescent and highly resistant to irradiation (Shao et al., 2010). On the contrary, 
transcription repressor Slug, also a p53 target, functions as an anti-apoptotic 
protein in HSPCS (Wu et al., 2005). A study from Look and colleagues 
suggested that Slug prevents the damaged HSPCs from apoptosis by directly 
repressing Puma gene expression. The activation of Slug in leukemic cells may 
attribute to their persistence in response to irradiation or chemotherapy, 
indicating a therapeutic strategy to inhibit Slug in cancer treatment (Wu et al., 
2005). 
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TP53 mutations  
1. Mechanisms of TP53 mutations          
Unlike most tumor suppressor genes, which are typically biallelic deleted 
during tumorigenesis, Tp53 is mostly inactivated by monoallelic missense 
mutations that lead to the formation of a stable full-length protein with the 
substitution of a single amino acid (Brosh et al., 2009; Freed-Pastor et al., 2012). 
The majority of the substitutions are located at the DNA-binding domain (DBD) of 
p53 and alter its sequence-specific DNA-binding activity, as shown in Figure 1.3 
(Brosh et al., 2009). As a result, these mutations may lost wild-type p53 activity, 
which is called “loss-of-function” (LOF) mutant. In addition, given that p53 
proteins function as a tetramer, mutant p53 proteins may dampen the activity of 
wild-type p53 and exert “dominant-negative” (DN) effect. Interestingly, numerous 
findings suggested some mutant p53 acquire oncogenic functions independent of 
wild-type p53 function, namely “gain-of-function” (GOF) mutant (Brosh et al., 
2009; Patricia et al., 2013). Introduction of mutant p53 into p53-/- cells generates 
new phenotypes, such as increased metastasis and genomic instability, in 
comparison to p53+/- and p53-/- cells. 
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Figure 1.4 Hot-spot p53 mutations identified in human 
cancer. 
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Accumulating studies have elucidated molecular mechanisms underlying 
mutant p53 driven tumorigenesis. Since most mutant p53 proteins still retain the 
N-terminal transcriptional transactivation domains, studies have been focused on 
their activity to directly regulate gene expression (Barlow et al., 2010). One 
amino acid is substituted within the DNA-binding domain of most mutant p53 
proteins, thereby the ability to bind WT p53 response elements is impaired. This 
raises one of the possible mechanism of action in that sequence-specific DNA 
binding activities are altered, resulting in unique mutant p53 response elements 
attributing to gain-of-function effect. Recently, it was published that mutant p53 
binds to and activates epigenetic regulatory genes, MLL1, MLL2 and MOZ, 
thereby promoting cancer cell proliferation (Zhu et al., 2015). Moreover, mutant 
p53 can interact with transcription machinery modulating their transcription 
activity. The interaction of mutant p53 with transcription factors could be 
simulation or inhibition. For example, in breast cancer cells, mutant p53 
cooperates with SWI/SNF chromatin remodeling complex and trans-activates 
VEGFR2 expression through remodeling its promoter (Pfister et al., 2015).  The 
other scenario is that mutant p53 directly interacts with some proteins and 
changes their functions which are not related to transcription. For instance, Xu 
and colleagues have discovered that mutant p53 directly interacts with MRE11, a 
DNA nuclease required for DNA repair, prevents MRN complex from 
phosphorylating ATM, leading to impaired DNA damaged repair and genome 
instability (Song et al., 2007). Other groups showed that wild-type p53 both 
promotes and inhibits topoisomerase 1 (Top1), which maintains topology of DNA. 
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In contrast, mutant p53 binds to Top1 and enhances its activity, resulting in 
hyper-recombination and loss of genome integrity (Muller et al., 2013).  
2. TP53 mutations in hematological malignancies 
The p53 pathway is activated upon a variety of stress conditions, allowing 
p53 to coordinate transcription programs that ultimately contribute to genome 
integrity and tumor suppression (Meek, 2009). When the Tp53 gene is mutated 
or the p53 pathway is compromised, cells are suspected to acquiring mutations 
or chromosome aberrations leading to cancer transformation (Meek, 2009; 
Brown et al., 2009). Indeed, p53 is the most frequently altered tumor suppressor 
in human cancers. More than 60% of solid tumors exhibit deletions or point 
mutations in the p53 genes (Hollstein et al., 1991; Hainaut et al., 1998), such as 
breast cancer, ovarian cancer and prostate cancer.  
In contrast to solid tumors, hematological malignancies present a relatively 
low frequency of alterations in this gene (Rucker et al., 2012; Muller et al., 2013). 
For example, TP53 is mutated in 10-20% of chronic lymphocytic leukemia (CLL), 
around 10% of AML, less than 3% in acute lymphoblastic leukemia (ALL), and 
10-12% cases of multiple myeloma (MM) (Peller et al., 2003; Harutyunyan et al., 
2011).  Of note, humans born with a single allele TP53 mutation, the Li–
Fraumeni syndrome, have an increased tendency to develop many types of 
cancer, including MDS and AML (Lang et al., 2004; Olive et al., 2004; Talwalkar 
et al., 2010). Nevertheless, clinical observations indicate that the survival rate of 
patients with p53 mutations is shorter than those with wild-type p53 in 
hematological malignancies, mainly due to poor prognosis, complex karyotype, 
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and drug resistance (Volkert, et al. 2014; Wong et al., 2015; Welch, et al 2016; 
Welch et al., 2016; Chang, et al. 2017;). TP53 mutated clones are often found to 
expand following treatment with lenalidomide, leading to resistance of the drug 
(Kulasekararaj et al., 2013). Moreover, alterations of p53 occur mostly in therapy-
related secondary AML and MDS in patients, with many of them carrying a 
further chromosome abnormities (Tehranchi et al., 2010; Sebaa et al., 2012; 
Metzgeroth et al., 2016). Furthermore, allogenic bone marrow transplantation, 
which is likely to be the most efficacy treatment for MDS patients, failed to 
improve the clinical outcome of those patients with TP53 mutations (Christopeit, 
et al. 2016; Lindsley, et al. 2017).  
Next generation sequencing (NGS) have allowed an understanding of the 
sequence of mutations in the evolution of primary AML and MDS. Recently, 
acquired somatic gain-of-function (GOF) p53 mutations were identified in the 
blood of aged healthy individuals as well as in MDS or/and AML patient 
(Genovese, et al. 2014; Jaiswal, et al. 2014). Moreover, TP53 are among the 
genes most common found to be altered in people with CHIP (Bejar et al., 2011).  
These evidences suggest that p53 mutations may be early events in the 
pathogenesis of the disease. However, further understanding of the origin of is 
still lacking. 
Apart from TP53 mutations or deletions, other mechanisms may 
negatively affect the expression and activity of wild-type p53, resulting in the loss 
of tumor suppression activity. The most compelling case is the elevated 
expression of MDM2, a negative regulator of p53 (Zhou et al., 2000). MDM2 is 
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transcriptionally activated by p53 and then binds to the N-terminal region of p53, 
thereby preventing p53 from interacting with the transcriptional programs and 
inducing proteasome-mediated degradation of p53 (Ringshausen et al., 2006).           
Although functions of mutant p53 in solid tumor have been well 
characterized, their role in hematological malignancies is poor understood. The 
effects of mutant p53 have been shown to be context dependent. Interactions 
that enhance activity in some circumstances may be inhibitory in others. 
Therefore, it is critical to decipher the mechanisms by which mutant p53 proteins 
initiate and drive hematological malignancies in order to gain better knowledge to 
develop therapeutic options for those dismal diseases with TP53 mutations. 
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Summary and Specific Aims 
Myelodysplastic syndrome (MDS) is characterized by ineffective 
hematopoiesis, multi-lineage morphological dysplasia and less than 5% blast 
cells with high risk to progress to acute myeloid leukemia (AML) (Nimer, 2008; 
Lindsley et al., 2013; Woll, et al., 2014; Sperling, et al., 2017;). Mutations on 
tumor suppressor gene TP53 present approximately 10% in MDS (Bejar et al., 
2014; Sperling, et al. 2017), whereas MDS patients with TP53 mutations are 
associated with a very dismal prognosis and respond unfavorably to 
chemotherapy (Chang, et al. 2017; Volkert, et al. 2014; Welch, et al 2016) , 
leading to shorter survival of these patients. Therefore, a better understanding of 
the pathogenesis of MDS with TP53 mutations is of great clinical significance. 
MDS is a clonal disease arising from the expansion of mutated 
hematopoietic stem cells (HSCs) (Nimer et al., 2008; Wong et al., 2015; Sperling 
et al., 2017). Accumulating studies indicate that the transformation event is 
initiated from the acquisition of pre-leukemic mutations driving the development 
of pre-leukemic HSCs, preceding the formation of fully transformed MDS stem 
cells (Bejar et al., 2011; Genovese et al., 2014; Jan et al., 2017). Pre-leukemic 
HSCs have competitive advantage compared to normal HSCs without affecting 
hematopoietic differentiation (Genovese et al., 2014). Recently, acquired somatic 
gain-of-function (GOF) mutations in TP53 gene have been identified in the blood 
of aged healthy individuals as well as in patients with MDS (Genovese et al., 
2014), implying the importance of TP53 mutations in the pre-leukemic phase of 
MDS development.  
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We have been investigating the role of tumor suppressor p53 in 
hematopoiesis and discovered that p53 maintains HSC quiescence and 
promotes DNA damage repair in response to irradiation (Liu et al., 2009b), 
suggesting a critical role of p53 in HSC function. Considering that mutations in 
TP53 alter the DNA-binding specificity of wild-type p53 (Brosh et al., 2009), 
mutant p53 proteins may utilize distinct “gain-of-function” mechanisms to regulate 
HSC behavior. This aspect of mutant p53 is largely unknown and need to be 
explored. 
Based on clinical evidence and our preliminary data, I hypothesized that 
GOF mutant p53 drives the development of pre-leukemic HSCs with 
enhanced competitive advantage, contributing to clonal expansion and the 
pathogenesis of MDS. The main objective of this study was to understand the 
biological impact and molecular basis of GOF mutant p53 in pre-leukemic HSCs 
and the pathogenesis of MDS. In this project, I specifically addressed the 
following specific aims: 
Specific Aim 1: Determine the role of GOF mutant p53 in 
hematopoietic stem cells. I hypothesized that mutant p53 enhances HSC self-
renewal without affecting terminal differentiation in order to drive the 
development of pre-leukemic HSCs. I performed serial competitive bone marrow 
transplantation, competitive HSC transplantation and limiting dilution assays to 
determine the role of mutant p53 in HSCs. (Chapter 3) 
Specific Aim 2: Determine the role of GOF mutant p53 in HSCs 
following genotoxic stress. I hypothesized that mutant p53 preserves HSC 
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function in response to genotoxic stress and promotes their clonal expansion. I 
challenged HSCs expressing mutant p53 with irradiation or the chemotherapeutic 
agent Fluorouracil (5-FU) and performed competitive transplantation assay to 
examine whether HSCs expressing mutant p53 are resistant to genotoxic stress. 
(Chapter 4) 
Specific Aim 3: Determine the role of GOF mutant p53 in the 
pathogenesis of MDS. I hypothesized that mutant p53 contributes to the 
pathogenesis of myelodysplastic syndrome in mice during ageing. I monitored 
the disease development of p53+/+ and p53R248W/+ mice to determine whether 
mutant p53 mice developed features recapitulating human myelodysplastic 
syndrome. (Chapter 5) 
Specific Aim 4: Elucidate the mechanisms by which GOF mutant p53 
drives the development of pre-leukemic HSCs. I hypothesized that mutant 
p53 promotes the development of pre-leukemic HSCs through regulating genes 
or/and pathways critical for HSC function. I utilized RNA-seq, gene expression 
profiling, and ATAC-seq assays to decipher the molecular mechanisms by which 
mutant p53 contributes to pre-leukemic HSC development. (Chapter 6) 
Specific Aim 5: Determine the interactions between GOF mutant p53 
and epigenetic regulators in HSCs. I hypothesized that mutant p53 interacts 
with epigenetic regulators to modulate genes or/and pathways essential for HSC 
maintenance. I performed biochemical experiments and ChIP-seq assay to 
explore how mutant p53 collaborates with epigenetic factors in regulating HSC 
self-renewal. (Chapter 7) 
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Significance 
Pre-leukemic HSCs may transform to leukemic stem cells, especially 
under stress conditions (Corces-Zimmerman et al., 2014; Shlush et al., 2014). 
Pre-leukemic HSCs are resistant to chemotherapy and serve as reservoirs for 
disease, generating new cancerous clones and leading to relapse (Corces-
Zimmerman et al., 2014; Shlush et al., 2014). A major barrier to development of 
effective therapeutics for hematological malignancies is lack of in-depth 
knowledge of the origins and the development of pre-leukemic HSCs. Therefore, 
there is a critical need to identify the aberrations and elucidate the underlying 
mechanisms that lead to pre-leukemic HSCs formation. While TP53 mutations 
have been identified in aged healthy individuals as well as patients with MDS, the 
role of mutant p53 in clonal hematopoiesis and pathogenesis of MDS is largely 
unknown. I discovered that GOF mutant p53 drives pre-leukemic HSC and MDS 
development through epigenetic modulation.  
Thus, our studies provide novel insights into the mechanisms of by which 
mutant p53 drives pre-leukemic HSC development. Understanding of the 
molecular basis of pre-leukemic HSC with p53 mutations has implication for 
cancer prevention at pre-malignant stage. Moreover, it will facilitate the 
development of therapeutic strategies that would be effectively in eliminating 
chemotherapy resistant pre-leukemic HSCs and MDS stem cells.  
Given that MDS patients with TP53 mutations are associated with a poor 
prognosis and bone marrow transplantation fails to improve their clinical 
outcomes (Chang, et al. 2017; Volkert, et al. 2014; Welch, et al 2016; Christopeit, 
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et al. 2016; Lindsley, et al. 2017), these patients are desperately in need of more 
effective therapeutic options. Therefore, our humanized mutant p53 knock-in 
p53R248W/+ mouse model provides a valuable research tool to study the 
pathogenesis of MDS with TP53 mutations and test novel therapeutic agents.  
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CHAPTER TWO 
Materials and methods 
Materials 
1. Mice 
All mice were maintained at the Indiana University Laboratory Animal 
Research Center (Indianapolis, IN, USA) according to the Institutional Animal 
Care and Use Committee (IACUC) of the Indiana University School of Medicine 
in the Indiana University Animal Facility.  
1.1 HUPKI (p53+/+) and p53R248W/+ mice 
The HUPKI (p53+/+) and p53R248W/+ mice used in our studies have been 
backcrossed to the C57BL6 background for 8 generations (Song et al., 2007). All 
young p53+/+ and p53R248W/+ mice used in these studies are 8 to 12 weeks old 
and are tumor free. We maintained both p53+/+ and p53R248W/+ mice for more than 
12 months for aging studies. 
1.2 C57BL/6 mice 
The C57BL/6 mice were purchased from the In Vivo Therapeutics Core at 
Indiana University School of Medicine. 
1.3 BoyJ mice 
The BoyJ mice were purchased from the In Vivo Therapeutics Core at 
Indiana University School of Medicine. 
1.4 F1 C57BL/6/ BoyJ mice 
The F1 mice were purchased from the In Vivo Therapeutics Core at 
Indiana University School of Medicine. 
36 
2. Primers 
Table 2.1 Primers 
 Gene Forward (5’-3’) Reverse (5’-3’) 
qPCR 
primer 
Actin GCCCTGAGGCTCTTTTCCAG 
TGCCACAGGATTCCATA
CCC 
p21 GACAAGAGGCCCAGTACTTC 
GCTTGGAGTGATAGAAA
TCTGTC 
Necdin GAGTTTGCCCTGGTCAAAGC 
CATAGATGAGGCTCAG
GATCATGA 
Mll1 CGGGCTCATCAACGATAAGC 
CAGGCCCAGATGTCAG
GTG 
Mll2 GGATCTATGACAGGGCTTTCCC 
ACCATGTGACATCATTC
CTTGC 
Moz GTGCTGCTACACCGATGGTG 
CTCTCGCTGAAGCCCCT
AAA 
Ezh2 CAATGATTTTGTGGTGGATG 
CAAAGATGCCTATCCTG
TGGT 
Cxcl9 GCCATGAAGTCCGCTGTTCT 
TAGGGTTCCTCGAACTC
CACA 
Sox2 GCGGAGTGGAAACTTTTGTCC 
CGGGAAGCGTGTACTTA
TCCTT 
Mef/Elf4 GCAGGACTGGAAAGGTTGCT 
CTGAGCCTCTGGGGAG
GATA 
Gadd45g GTCCTGAATGTGGACCCTGA 
GCAGAACGCCTGAATCA
ACG 
ChIP-
qPCR 
primer 
ELF4-TSS CTGCACTTTAAGCGGCCTTC 
TCTCTTGAGTCAGCGGA
TCG 
ELF4-UP 100 TTATTTCTTGCTCCCGCCCC 
GGACTCACTTTCCTCCC
AGC 
Gadd45g-TSS CGCGCCGAGCCTGTCTATAA 
AAGATTCCCAGAGTCCG
ATGC 
Gadd45g-UPS GCATCAGAAAGCGGGCG 
GCCGGGAGAGCCCTTT
TAT 
Gadd45g-
Down 
CATTGATATCGTGCG
CGTGG 
GGGGGACACTCACCGA
AATG 
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3. Antibodies 
Table 2.2 Antibodies 
Antibody Company Catalog Number 
CD3-PE   Biolegend 145-2C11  
B220-PECY7 Biolegend RA3-6B2  
Gr-1-APC  Biolegend  RB6-8C5  
Mac1-APC Biolegend M1/70  
Ter119-FITC Biolegend TER-119  
CD45.2-FITC  Biolegend 104  
CD45.1-PE Biolegend 2B8  
CD48-PE  eBioscience  HM48-1  
CD150-Percpcy5.5 eBioscience  TC15-12F12.2  
cKit-APC  eBioscience  2B8  
CD16/CD32-PE-Cy7 eBioscience  93  
Sca-1-PE-Cy7  eBioscience  D7  
CD34-FITC  eBioscience  RAM34  
Strepdividin-APCcy7 eBioscience  RA3-6B2 
Sca-1-Percpcy5.5 eBioscience D7 
 
4. Commercial Kits 
Table 2.3 Commercial Kits 
                         Kit Company Catalog Number 
EZ ChIP Chromatin 
Immunoprecipitation Kit  Millipore 17-371 
Lin- Cell Depletion Kit, mouse  
 
Miltenyi Biotec 130-090-858 
PE Mouse Anti-Human Ki-67 BD Pharmingen 556027 
FastStart Universal SYBR Green 
Master (Rox) Roche 04913850001 
MicroRNA Reverse Transcription 
Kit  Qiagen 4366596  
GeneJET PCR purification Kit Thermo Scientific K0702 
RNeasy Plus Micro Kit Qiagen 74034 
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5. Reagents 
Table 2.4 Reagents 
Reagent Company Catalog Number 
RIPA buffer Sigma R0278 
NuPAGE 10% Bis-Tris Gel Life technologies NP0316BOX 
Immobilon Western HRP Substrate 
Peroxide Solution Millipore 16144B2 
SuperSignal West Femto Thermo Scientific 1856190 
Protease Inhibitor Roche  
Streptavidin MicroBeads Miltenyi Biotec 
 
130-048-101 
APC Annexin V Biolegend 640920 
FITC Annexin V Biolegend 640906 
10x Annexin V Binding Buffer BD Pharmingen 51-66121E 
Red Blood Cell Lysis Solution (10x) Miltenyi Biotec 130-094-183 
SuperScript IV First-Strand Synthesis 
System Invitrogen 18091050 
MethoCult GF M3434 StemCell 03434 
GoTag G2 Hot Start Green Master  
Mix Promega M7423 
 
Methods 
1. Stem and progenitor cell assays 
Progenitors as assayed by colony formation were determined in 
methylcellulose medium (MethoCult GF M3234, StemCell Technologies) using 2 
x 104 BM cells per well (6-well plate). Colonies were scored after 7 days of the 
initial culture, and all cells were collected and washed twice in PBS. 
Subsequently cells were cultured at 2 x104 per well in the same medium. Colony 
scoring and replating were repeated every 7 days at least two times, or until no 
colonies were observed in the cultures.  
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2. Flow cytometry  
Flow cytometry analysis of hematopoietic stem and progenitor cells was 
performed as described previously (Liu et al., 2009b). Murine hematopoietic stem 
and progenitor cells were identified and evaluated by flow cytometry using a 
single cell suspension of bone marrow mononuclear cells (BMMCs). 
Hematopoietic stem and progenitors are purified based upon the expression of 
surface markers listed in the Table 1.1 (See page 5). Bone marrow (BM) cells 
were obtained from tibia, femur and iliac crest (6 from each mice) by flushing 
cells out of the bone using a syringe and phosphate-buffered saline (PBS) with 
2mM EDTA. Red blood cells (RBCs) were lysed by RBC lysis buffer 
(eBioscience) listed in Table 2.4 prior to staining by antibodies listed in Table 2.2. 
Experiments were performed on FACS LSR IV cytometers (BD Biosciences) and 
analyzed by using the FlowJo Version 9.3.3 software (TreeStar). 
3. Ki-67 staining 
Bone marrows were stained for cell surface markers as described above. 
After staining, cells were washed with 0.2% BSA in PBS, fixed and permeabilized 
using Cytofix/Cytoperm buffer (BD Biosciences) listed in Table 2.3 and then 
incubated with PE-conjugated-antibody against Ki-67 (BD Biosciences) for more 
than 30 minutes on ice. Cells were washed, incubated with 4′,6-diamidino-2-
phenylindole (DAPI) (Sigma) and acquired using LSR IV flow cytometer machine. 
Data analysis was performed using FlowJo software. 
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4. AnnexinV staining 
Bone marrows were stained for cell surface markers as described above. 
After staining, cells were washed with 0.2% BSA in PBS, and then suspended in 
1X AnnexinV-binding buffer listed in Table 2.4. Suspended cells were stained 
with FITC-conjugated-AnnexinV (BD Biosciences) for 30 minutes at room 
temperature. DAPI (Sigma) was then added to cell suspension and LSR IV flow 
cytometer machine was used for acquisition. Data analysis was performed using 
FlowJo software 
5. Transplantation  
5.1 Competitive bone marrow transplantation 
We injected 5 x 105 total BM cells from p53+/+ and p53R248W/+ mice 
(CD45.2+) plus 5 x 105 competitor total BM cells (CD45.1+) into 9.5Gy lethally 
irradiated F1 mice (CD45.1+CD45.2+). Peripheral blood was obtained by tail vein 
bleeding every 4-week after transplantation, RBC lysed, and the PB mononuclear 
cells stained with anti-CD45.2 FITC and anti-CD45.1 PE, and analyzed by flow 
cytometry. 16 weeks following transplantation, bone marrow cells from recipient 
mice were analyzed to evaluate donor chimerism in bone marrows. For 
secondary transplantation, 3X106 BM cells from mice reconstituted with p53+/+ or 
p53R248W/+ BM cells were injected into 9.5Gy lethally irradiated F1 mice 
(CD45.1+CD45.2+).  
5.2 Competitive HSC transplantation 
We injected 200 CD48-CD150+LSK cells from p53+/+ and p53R248W/+ mice 
(CD45.2+) plus 3 x 105 competitor bone marrow cells (CD45.1+) into lethally 
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irradiated F1 mice (CD45.1+CD45.2+). The percentage of donor-derived 
(CD45.2+) cells in peripheral blood was analyzed every 4 weeks after 
transplantation as described above. 16 weeks following transplantation, we 
harvested bone marrow cells from recipient mice and performed flow cytometry 
analysis to evaluate HSC repopulating capability.  
5.3 Whole bone marrow transplantation 
Recipient mice were lethally irradiated (9.5Gy) followed by injection of 1 x 
106 to 3 x 106 BM cells from p53+/+ and p53R248W/+ mice. 
6. Limiting dilution assay 
Different doses (10,000, 20,000, 40,000, 80,000) of BM cells from p53+/+ 
and p53R248W/+ mice (CD45.2+) with 200,000 competitor cells (CD45.1+) were 
transplanted into lethally irradiated (9.5Gy)  F1 recipient mice (CD45.2+CD45.1+). 
The percentage of donor-derived (CD45.2+) cells were analyzed 16-week 
following transplantation as described above. HSC frequency was calculated 
using L-Calc software (StemCell Technologies Inc.) and ELDA software 
(bioinf.wehi.edu.au/software/elda/). Poisson statistics was used to calculate the p 
value. 
7. Homing assays 
1 x 107 p53+/+ and p53R248W/+ BM cells (CD45.2+) were injected into lethally 
irradiated recipient mice (CD45.1+). BM cells were harvested 18 hours following 
injection and the frequency of donor-derived cells (CD45.2+) was evaluated by 
flow cytometry. 
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8. Histology 
All tissue samples were collected following a detailed LARC approved lab 
animal protocol. Tissues were fixed overnight at room temperature in 10% NBF 
after which they were transferred through graded concentrations of alcohol to 
xylene inside a Leica Automated Vacuum Tissue Processor. They were 
embedded in paraffin before being sliced into five micron thick sections, mounted 
onto positively charged slides, and baked at 60 °C.  The slides were stained with 
H&E for pathologic evaluation.   
9. Quantitative Real-Time PCR (qRT-PCR)  
Total RNA was extracted from cells using RNeasy Plus Micro Kit (Qiagen) 
in Table 2.3 and cDNA was prepared from total RNA using SuperScript IV First-
Strand cDNA Synthesis Kit (Invitrogen Life Technologies) and oligo (dT) primers, 
following manufacturer’s instructions. qRT- PCR assay was performed by using 
the 7500 Real Time PCR machine (Applied Biosystems) with FastStart Universal 
SYBR Green Master (ROX) (Roche). Primers for PCR are listed in Table 2.1. 
10. Quantification of γ-H2Ax by ImageStream Flow Cytometry 
Lineage-depleted BM cells were first stained with antibodies against 
appropriate HSPC surface markers, then fixed and permeabilized using the 
Cytofix/Cytoperm Kit (BD Biosciences), as described by the manufacturer, and 
finally stained with an Alexa-488-conjugated anti- γ-H2Ax antibody (Cell 
Signaling Technology). 
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11. Quantification of H3K27me3 by ImageStream Flow Cytometry 
Lineage-depleted BM cells were first stained with antibodies against 
HSPC surface markers, then fixed and permeabilized using the Cytofix/Cytoperm 
Kit (BD Biosciences), as described by the manufacturer, and finally stained with 
an Alexa-488-conjugated anti- H3K27me3. 
12. Co-IP 
Co-Immunoprecipitation (Co-IP) experiments were performed as 
described previously (Gao et al., Mol Cell 2012) with certain modifications. 
H1299 cells were co-transfected with FLAG-HA-EZH2 and wild-type or mutant 
p53, respectively, or transfected with FLAG-HA-EZH2 alone. Nuclear extract was 
prepared from these cells and incubated with a polyclonal p53 antibody (FL393) 
(Santa Cruz) prior to addition of protein G beads. After overnight incubation, 
beads were then washed 5 times and eluted with glycine (0.1 M, pH 2.0), and 
then neutralized by adding Tris solution (1.5 M, pH 8.8). The eluates were mixed 
with SDS sample buffer and analyzed by SDS-PAGE, followed by 
immunoblotting.  
13. RNA sequencing 
Total RNA is extracted from cells using RNeasy MicroPlus Kit (Qiagen). 
Then the mRNA is enriched with the oligo (dT) magnetic beads (for eukaryotes), 
and is fragmented into short fragments (about 100 bp). With random hexamer-
primer, the first strand of cDNA is synthesized, and then the second strand is 
synthesized. The double strand cDNA is purified with magnetic beads. The ends 
of the double strand cDNA are repaired, and a single nucleotide A (adenine) is 
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added to the 3′-ends. Finally, sequencing adaptors are ligated to the fragments. 
The ligation products are amplified with PCR. For quality control, RNA and library 
preparation integrity are verified using Agilent 2100 BioAnalyzer system and ABI 
StepOnePlus Real-Time PCR System. RNA sequencing library was then 
constructed and then sequenced with Hiseq 4000. Gene Set Enrichment 
Analysis (GSEA) (Subramanian et al., 2005) was performed on gene sets from 
the Molecular Signatures Database (MSigDB, 
https://www.broadinstitute.org/msigdb) and additional gene sets curated from 
publications. Gene sets with FDR q-value < 0.05 were considered significantly 
enriched.  
14. Expression microarray analysis 
Transcript profiling of p53+/+ and p53R248W/+ HSCs (CD48-CD150+LSKs) 
were analyzed by Agilent Whole Mouse Genome Oligo Microarrays. Raw data 
will be available for download from Gene Expression Omnibus 
(http://ncbi.nlm.nih.gov/geo/, accession number x). For data analysis, CEL files 
were analyzed using GenePattern (Broad Institute) according to current 
protocols. Pearson correlation values were determined from all genes that 
passed normalization and filters. Gene Set Enrichment Analysis (GSEA) was 
conducted according to current protocols. 
15. Chromatin immunoprecipitation sequencing (ChIP-seq) 
Cells were fixed with 1% formaldehyde for 15 min and quenched with 
0.125 M glycine. Chromatin was isolated by the addition of lysis buffer, followed 
by disruption with a Dounce homogenizer. Lysates were sonicated and the DNA 
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sheared to an average length of 300-500 bp. Genomic DNA (Input) was prepared 
by treating aliquots of chromatin with RNase, proteinase K and heat for de-
crosslinking, followed by ethanol precipitation. Pellets were resuspended and the 
resulting DNA was quantified on a NanoDrop spectrophotometer. An aliquot of 
chromatin (30 ug) was precleared with protein A agarose beads (Invitrogen). 
Genomic DNA regions of interest were isolated using 4 ug of antibody against 
Histone H3K27me3 (clone: 39155, Active Motif) Complexes were washed, eluted 
from the beads with SDS buffer, and subjected to RNase and proteinase K 
treatment. Crosslinks were reversed by incubation overnight at 65 C, and ChIP 
DNA was purified by phenol-chloroform extraction and ethanol precipitation. 
Illumina sequencing libraries were prepared from the ChIP and Input DNAs by 
the standard consecutive enzymatic steps of end-polishing, dA-addition, and 
adaptor ligation. After a final PCR amplification step, the resulting DNA libraries 
were quantified and sequenced on Illumina’s NextSeq 500 (75 nt reads, single 
end). Reads were aligned to the mouse genome (mm10) using the BWA 
algorithm (default settings). Duplicate reads were removed and only uniquely 
mapped reads (mapping quality >= 25) were used for further analysis. 
Alignments were extended in silico at their 3’-ends to a length of 200 bp, 
which is the average genomic fragment length in the size-selected library, and 
assigned to 32-nt bins along the genome. The resulting histograms (genomic 
“signal maps”) were stored in bigWig files. H3K27me3 enriched regions were 
identified using the SICER algorithm with a MaxGap parameter setting of 600 bp. 
Signal maps and peak locations were used as input data to Active Motifs 
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proprietary analysis program, which creates Excel tables containing detailed 
information on sample comparison, peak metrics, peak locations and gene 
annotations. 
16. ATAC sequencing 
100,000 p53+/+ and p53R248W/+ LSK cells were harvested and frozen in 
culture media containing 5% DMSO. Frozen cells were sent to Active Motif to 
perform the Open Chromatin Sequencing Assay.  The cells were then thawed in 
a 37oC water bath, pelleted, washed with cold PBS, and tagmented as previously 
described (Buenrostro et al. 2013), with some modifications. Briefly, cell pellets 
were resuspended in lysis buffer, pelleted, and tagmented using the enzyme and 
buffer provided in the Nextera Library Prep Kit (Illumina). Tagmented DNA was 
then purified using the MinElute PCR purification kit (Qiagen), amplified with 10 
cycles of PCR, and purified.  Resulting material was quantified using the KAPA 
Library Quantification Kit for Illumina platforms (KAPA Biosystems), and 
sequenced with PE42 sequencing on the NextSeq 500 sequencer (Illumina). 
17. Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6 software 
(GraphPad software, Inc). All data are presented as mean ± standard error of the 
mean (SEM). The sample size for each experiment and the replicate number of 
experiments are included in the figure legends. Statistical analyses were 
performed using unpaired, two-tailed Student’s t test where applicable for 
comparison between two groups, and a One-way ANOVA test or Two-way 
ANOVA was used for experiments involving more than two groups. Statistical 
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significance was defined as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; 
ns, not significant. 
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CHAPTER THREE 
GOF mutant p53 enhances the repopulating potential of hematopoietic 
stem cells 
Introduction 
We have been investigating the role of tumor suppressor p53 in normal 
hematopoiesis. We have discovered that p53 regulates HSC quiescence by 
analyzing the p53 knock out mice at the age of two to three months (Liu et al., 
2009b). In addition, studies from other groups suggest that p53 regulates 
proliferation, differentiation and ageing in HSCs (Kastan et al., 1991; Shounan et 
al., 1996; Park et al., 2003; Liu et al., 2009a). Given that p53 is a critical regulator 
of HSCs, alteration of p53 may lead to overt blood malignancies. Indeed, TP53 
mutations are found in approximately 10% AML or MDS patients (Rücker, et al. 
2012; Sperling, et al. 2017). Moreover, among AML patients with complex 
karyotypes, the frequency of TP53 mutations and/or deletions is almost 70% 
(Chang, et al. 2017; Volkert, et al. 2014; Welch, et al 2016). Previously, TP53 
mutations and/or deletions were regarded as secondary events in the evolution 
of leukemia (Harutyunyan et al., 2011). However, TP53 mutations have recently 
been found in the blood of aged healthy individuals by next generation 
sequencing studies, and TP53 mutations have been identified as one of the most 
common alterations in clonal hematopoiesis (Genovese et al., 2014). These 
findings implicate a role forTP53 mutations in the early steps of leukemia 
development. Therefore, it was tempting for us to study whether TP53 mutations 
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are pre-leukemic mutations that drive the development of pre-leukemic 
hematopoietic stem cells. 
p53 knock-out mice have been widely used to determine the role of the 
p53 pathway in hematopoietic malignancy (Liu et al., 2009b). However, TP53 
deletions are mainly found in advanced phase of hematological malignancies 
(Harutyunyan et al., 2011). Further, most TP53 mutations in AML or MDS are 
mono-allele missense mutations which can have dominant negative effects 
and/or gain-of-function (GOF) features (Freed-Pastor et al., 2012). These 
aspects of TP53 mutations in regulating HSC behavior cannot be delineated by 
using p53-/- mice. Thus, the role of TP53 mutations in the pathogenesis of MDS 
and leukemia remains elusive.           
In order to study the role of TP53 mutations in HSCs, we performed a 
functional screening of 8 hot-spot TP53 mutations identified in AML or MDS 
(Barlow et al., 2010). The experimental designs were illustrated in Figure 3.1 A. 
Briefly, hotspot p53 mutants were introduced into WT fetal live cells and 
transduced cells (GFP+) cells were then utilized to perform serial replating 
assays. Some of the mutants, including p53R248W, p53R273H, p53Y220C, p53R175H, 
p53R248Q, and p53C238Y, enhanced the serial replating potential of HSPCs in vitro 
compared to control viruses (MIGR1) transduced cells (Figure 3.1.B). 
Competitive transplantation assays were then performed to determine the role of 
some GOF p53 mutants, such as p53R248W, p53R273H and p53Y220C, in HSCs in 
vivo. We found that ectopic expression of GOF mutant p53 proteins enhance the 
repopulating potential of murine hematopoietic stem and progenitor cells (Figure 
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3.1.C). Our data indicate that GOF mutant p53 may enhance the repopulating 
potential of HSCs in vivo.           
Based upon our preliminary studies and clinical findings, I hypothesized 
that GOF mutant p53 increases the competitive advantage of HSCs without 
impairing normal differentiation, leading to the development of pre-
leukemic hematopoietic stem cells.            
To test this hypothesis, I investigated the function of mutant p53 in HSCs 
utilizing mouse models. I focused on studying p53R248W mutant as codon R248 of 
p53 is most frequently mutated in myeloid malignancies (Rücker et al., 2012; 
Welch et al., 2016). Moreover, mutations on R248 codon have been found in the 
blood of aged healthy people (Genovese et al., 2014). I, therefore, utilized the 
humanized p53R248Wmice, where the humanp53 protein is expressed from the 
endogenous murine Trp53 promoter. I examined HSC behavior in young adult (2-
3 month old) p53+/+ and p53R248W/+ mice. SLAM cell surface markers were used to 
determine the frequency of immunophenotypic LT-HSCs in mice. I analyzed the 
frequency of quiescent and apoptotic HSCs utilizing Ki67 and Annexin V staining. 
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Figure 3.1 Functional screening of mutant p53 in hematopoietic stem 
cells. 
(A)  Hot-spot p53 mutants were introduced into wild type fetal liver cells 
using retrovirus-mediated transduction. In vitro and in vivo stem and 
progenitor cell assays were then performed using sorted GFP+ cells.
(B) Serial replating assays of fetal liver cells transduced with p53 mutants. 
**p<0.01, ***p<0.001, n=3. 
(C) Percentage of GFP+ cells in the peripheral blood of recipient mice 
following competitive transplantation. n=5 mice per group, *p<0.05, 
***p<0.001, ****p<0.0001. 
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HSCs have the capacity to provide long-term reconstitution of all 
hematopoietic lineages upon transplantation into lethally irradiated mice (Orkin et 
al., 2008). Thus, serial competitive transplantation assay is the gold standard to 
measure HSC self-renewal capability in vivo (Orkin et al., 2008; Ng et al., 2017). I 
first performed serial competitive bone marrow transplantation and competitive 
HSC transplantation assays in order to investigate whether heterozygote 
p53R248W mutant has an impact on HSC self-renewal and differentiation in vivo.  I 
also performed limiting dilution assay to quantify the number of functional HSCs 
in the BM of p53+/+ and p53R248W/+ mice. Homing assay was conducted in order to 
evaluate whether p53R248W mutant affects HSC homing ability in transplantation 
settings. My ultimate goal is to determine the role of mutant p53 in the 
development of pre-leukemic HSCs. 
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Results 
1. GOF mutant p53 does not affect HSC frequency 
In our preliminary studies, we showed that some hot-spot GOF mutant 
p53 proteins, including p53R248W, p53R273H, and p53Y220C, enhances the 
repopulating potential of fetal liver cells in vivo (Figure 3.1.C).  However, the role 
of GOF mutant p53 in HSC self-renewal and differentiation in vivo is not known. 
Codon 248 of the p53 protein (p53R248) is most frequently mutated in MDS and 
AML (Rücker et al., 2012; Welch et al., 2016). In addition, mutations in p53R248 
(p53R248Q and p53R248W) were identified in aged healthy individuals and were 
found further proceed the development of AML (Genovese et al., 2014; Wong et 
al., 2015). Therefore, I focused on studying the role of p53R248W in HSC 
regulation. Considering that over-expression of mutant p53 from a MSCV 
promoter may not reflect accurate function at physiological levels, I used 
p53R248W knock-in mice where p53R248W was introduced into the humanized p53 
knock-in (HUPKI) allele in mice, expressing human p53 mutant protein from the 
endogenous murine Trp53 promoter (Song et al., 2007). The HUPKI allele 
encodes a human/mouse chimeric protein consisting primarily of human p53 
sequence (amino acids 33–332) flanked by the conserved extreme amino and 
carboxyl-termini of mouse p53 (Luo et al., 2001). HUPKI mice were described as 
p53+/+ mice in the text below.           
Most TP53 mutations in hematological malignancies are mono-allele 
missense mutations. To mimic clinical situations, I utilized heterozygous 
p53R248W/+ mice to study how mutant p53 affects HSC behavior. Analysis of bone 
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marrow (BM) of young (8 to 12 week-old) p53+/+ and p53R248W/+ mice revealed 
that p53R248W/+ and p53+/+ mice have comparable bone marrow cellularity. (Figure 
3.2.A). To examine the frequency of primitive HSPCs in BM, I then performed 
flow cytometry based on SLAM surface markers to distinguish LT-HSCs (Lin-
Sca1+c-kit+CD150+CD48-), ST-HSCs (Lin-Sca1+c-kit+CD150-CD48-), MPPs (Lin-
Sca1+c-kit+CD150-CD48+) and LSKs (Lin-Sca1+c-kit+) population in the BM 
(Figure 3.2.B). Interestingly, expression of p53R248W does not affect the frequency 
of LT-HSCs, ST-HSCs, MPPs and LSK cells (Figure 3.2.C). I also found that the 
frequency of hematopoietic progenitor cells, including MEPs, GMPs and CMPs, 
are comparable between p53R248W/+ and p53+/+ mice (Figure 3.2.B and Figure 
3.2.D).            
Collectively, p53R248W/+ does not affect immunophenotypic hematopoietic 
stem and progenitor cells during steady state hematopoiesis. 
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Figure 3.2 Mutant p53 does not affect the frequency of hematopoietic 
stem and progenitor cells. 
(A)  Bone marrow cell numbers from p53+/+ and p53R248W/+ mice (8 to 12 
weeks old). n=10 mice per group. 
(B) Representative flow cytometry plots of hematopoietic stem and 
progenitor cells gating were shown. 
(C) The frequency of LT-HSCs, ST-HSCs, MPPs, and LSKs in the BM of 
p53+/+ and p53R248W/+ mice. n=10 mice per genotype. 
(D) The frequency of CMPs, MEPs, and GMPs in the bone marrow of 
p53+/+ and p53R248W/+ mice. n=10 mice per genotype. 
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2. GOF mutant p53 does not affect HSC survival in steady state 
hematopoiesis 
Wild-type p53 plays a critical role in programmed cells death (Bálint et al., 
2001). Given that wild-type p53 activates Bax, a pro-apoptotic protein of the BCL-
12 family, loss of p53 decreases cell apoptosis (Mihara et al. 2003). While we 
reported that wild-type p53 is important for HSC survival (Liu et al., 2009b), the 
impact of GOF mutant p53 on HSC survival in steady state remains elusive.  
Therefore, I examined whether p53R248W mutant affect apoptosis of HSCs in 
steady state. AnnexinV and DAPI staining were then performed in freshly 
isolated BM cells following cell surface markers staining to determine the 
apoptotic state of HSCs. The early apoptotic cells are positively stained for 
Annexin V but not for DAPI, shown as the left lower panel on the profile. (Figure 
3.3.A). Flow cytometry analysis showed no change in the apoptosis of p53R248W/+ 
HSCs compared to p53+/+ HSCs (Figure 3.3.B), suggesting that mutant p53 does 
not affect the survival of HSC in steady state. 
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Figure 3.3 Mutant p53 does not affect survival of hematopoietic stem 
cells. 
(A)  Representative flow cytometry plots of Annexin V and DAPI staining of 
hematopoietic stem cells were shown. 
(B) The percentage of early apoptotic p53+/+ and p53R248W/+ hematopoietic 
stem and progenitor cells was measured by Annexin V and DAPI staining. 
n=4 mice per genotype. 
Annexin-V
DA
PI
p53+/+ p53R248W/+
A 
60 
3. GOF mutant p53 does not affect HSC quiescence in steady state 
Quiescence (G0) is a physiological state where cells exit the cell cycle and 
remain dormant (Orkin et al., 2008). It has been well established that most HSCs 
in an organism are quiescent in order to maintain long-term self-renewal potential 
and to prevent the stem cell pool from exhaustion (Orkin et al., 2008; Ng et al., 
2017). In response to stress signals or cytokine stimulations, quiescent HSCs 
enter the cell cycle to replenish hematopoietic system and self-renew to maintain 
the stem cell pool (Zon et al., 2008). In addition, quiescence protects HSCs from 
acquiring mutations, decreasing the risk of leukemic transformation (Orkin et al., 
2000; Orkin et al., 2008; Ng et al., 2017).  
Ki67 is a cell proliferation marker that is commonly used for examining cell 
proliferation. The size of quiescent (G0) stem cell pool can be determined by the 
absence of the proliferation marker Ki67 (Figure 3.4.A). Wild-type p53 maintains 
HSC quiescence as loss of p53 enhances HSC proliferation (Liu et al., 2009b). 
However, I observed no significant change on the quiescent state of p53R248W/+ 
HSCs compared to p53+/+ HSCs as assessed by Ki67 and DAPI staining (Figure 
3.4.B), suggesting that p53R248W mutant does not affect HSC quiescence in 
steady state. 
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Figure 3.4 Mutant p53 does not affect quiescence of hematopoietic 
stem cells. 
(A) Representative flow cytometry plots of Ki67 and DAPI staining of 
hematopoietic stem and progenitor cells were shown. 
(B) The percentage of quiescent (G0) hematopoietic stem and progenitor 
cells was measured by Ki67 and DAPI staining. n=5 mice per genotype. 
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4. GOF mutant p53 enhances the repopulating potential of HSCs without 
affecting terminal differentiation 
The serial replating assay assesses the preservation of “stemness” in 
progenitor compartment (Liu et al., 2009b). We performed CFU assays using 
20,000 BM cells from young p53+/+ and p53R248W/+ mice and found that p53R248W/+ 
bone marrow cells showed increased replating potential compared to p53+/+ bone 
marrows. (Figure 3.5), implicating a positive role of p53R248W in regulating HSC 
self-renewal in vivo. 
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Figure 3.5 Mutant p53 enhances the replating potential of 
hematopoietic progenitor cells. 
Serial replating studies. Myeloid progenitors were quantified by 
methylcellulose culture using BM cells from p53+/+ and p53R248W/+ mice. 
The methylcellulose cultures were serially replated, weekly, for 3 weeks. n 
= 3 per genotype, **p<0.01, ****p<0.0001. 
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To determine the impact of mutant p53 on HSC functions in vivo, I first 
performed serial competitive bone marrow transplantation assays, where 5 x 105 
donor BM cells (p53+/+ or p53R248W/+, CD45.2+) were transplanted into lethally 
irradiated (9.5 Gy) F1 recipient mice (CD45.1+CD45.2+) along with 5 x 105 
competitor BM cells (CD45.1+). 16 weeks after transplantation, the repopulating 
potential of p53R248W/+ BM cells was significantly higher than that of the wild type 
cells, reflecting by increased percentage of donor-derived (CD45.2+) in the 
peripheral blood (PB) and BM of recipient mice (Figure 3.6.A and 3.6.B). 
Moreover, the percentage of CD45.2+ HSCs and progenitors in the BM of 
recipient mice repopulated with p53R248W/+ BM cells were significantly higher than 
those from p53+/+ group (Figures 3.6.C and 3.6.D). However, p53R248W did not 
affect myeloid and lymphoid differentiation in both PB and BM of primary 
recipients (Figure 3.6.E and 3.6.F). I then transplanted 3 x 106 BM cells isolated 
from the primary recipient mice repopulated with p53+/+ or p53R248W/+ cells into 
lethally irradiated secondary F1 recipients. p53R248W/+ cells continued to show 
increased repopulating ability compared to p53+/+ cells (Figure 3.6.G). No 
changes in myeloid and lymphoid differentiation were observed in peripheral 
blood of secondary transplantation recipients at 16-week post transplantation 
(Figure 3.6.H).  
Thus, I demonstrated that p53R248W/+ enhances repopulating potential of 
HSCs without affecting myeloid and lymphoid differentiation in serial competitive 
bone marrow transplantation experiments. 
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Figure 3.6 Mutant p53 enhances repopulating potential of 
hematopoietic stem cells in serial competitive bone marrow 
transplantations. 
(A)  Percentage of donor-derived (CD45.2+) cells in the peripheral blood of 
primary recipient mice post-transplantation, measured at 4-week intervals. 
n=7 mice per group, **p<0.01, ***p<0.001.  
(B) The percentage of donor-derived cells (CD45.2+) in the bone marrow of 
primary recipient mice 16 weeks following transplantation was determined 
by flow cytometry analysis. n = 7 mice per group, *p<0.05. 
(C) The frequency of donor-derived LT-HSCs, ST-HSCs, MPPs, and LSK 
cells in the bone marrow of primary recipient mice 16 weeks following 
transplantation was determined by flow cytometry analysis. n = 7 mice per 
group, *p<0.05, ***p<0.001, ***p<0.0001. 
(D) The frequency of donor-derived MEPs, CMPs, GMPs, and Lin-Kit+ cells 
in the bone marrow of primary recipient mice 16 weeks following 
transplantation was determined by flow cytometry analysis. n = 7 mice per 
group, *p<0.05, **p<0.01. 
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(E) Percentage of donor-derived myeloid cells (Gr1+), B cells (B220+) and 
T cells (CD3+) in the peripheral blood of primary recipient mice 16 weeks 
following transplantation. n=7 mice per group. 
(F) The frequency of myeloid cells (Gr1+), B cells (B220+) and T cells 
(CD3+) in donor-derived bone marrow of the primary recipient mice 16 
weeks following transplantation was determined by flow cytometry 
analysis. n = 7 mice per group. 
(G) Percentage of donor-derived cells in the peripheral blood of secondary 
recipient mice. n=7 mice per group, ***p<0.001 
(H) The frequency of myeloid cells (Gr1+), B cells (B220+) and T cells 
(CD3+) in donor-derived peripheral blood of the secondary recipient mice 
16 weeks following transplantation was determined by flow cytometry 
analysis. n = 7 mice per group. 
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To further determine whether mutant p53 affects HSC self-renewal and 
differentiation, I transplanted 200 purified CD45.2+ p53+/+ and p53R248W/+ HSCs 
(CD48-CD150+LSKs) into 9.5Gy lethally irradiated F1 recipient mice along with 
300,000 wild-type competitor CD45.1+ BM cells. I found that p53R248W/+ HSCs 
exhibited a substantially higher reconstitution to peripheral blood production 
compared to p53+/+ HSCs (Figure 3.7.A). Consistent with serial competitive BM 
transplantation assays, p53R248W did not affect myeloid and lymphoid 
differentiation in bone marrows and peripheral blood of recipient mice 16-week 
following transplantation (Figure 3.7.B).  Interestingly, the absolute numbers of 
CD45.2+ HSCs in the BM of recipient mice repopulated with p53R248W/+ HSCs 
was significantly higher than that of the p53+/+ HSCs (Figure 3.7.C), suggesting 
mutant p53 enhances the repopulating potential of HSCs in competitive 
transplantation assays.           
To quantify the numbers of functional HSCs in the BM of p53R248W/+ mice, I 
then performed competitive BM transplantation experiments with different dose of 
donor cells.  Calculating the number of non-engrafted recipient mice revealed 
that the frequency of competitive repopulation units (CRU) in the BM of 
p53R248W/+ mice is 3 to 4 fold higher than that of the p53+/+ mice (Figures 3.8.A 
and 3.8.B), indicating that there are more functional HSCs in p53R248W/+ mice 
compared to that of p53+/+ mice.           
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Figure 3.7 Mutant p53 enhances the repopulating potential of 
hematopoietic stem cells in competitive HSC transplantation. 
(A)  Percentage of donor-derived cells in the peripheral blood of recipient 
mice flowing HSC transplantation. n=7 mice per group, **p<0.01, 
***p<0.001. 
(B) Absolute number of donor-derived LT-HSCs in the BM of recipient mice 
16 weeks following HSC transplantation. n=6 mice per group, **p<0.01. 
(C) The frequency of myeloid cells (Gr1+), B cells (B220+) and T cells 
(CD3+) in donor-derived bone marrow of the secondary recipient mice 16 
weeks following transplantation was determined by flow cytometry 
analysis. n = 7 mice per group. 
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Figure 3.8 Limiting dilution assays show that mutant p53 increases 
the number of functional HSCs in vivo. 
(A)  Measuring HSC frequency in the BM of p53+/+ and p53R248W/+ mice 
utilizing limiting dilution assays. Recipients with less than 2% donor-
derived cells in the peripheral blood were defined as non-respondent. n=7-
10 mice per group, **p<0.01. 
(B) Poisson statistical analysis of data from Figure 2H using L-Calc 
software. Shapes represent the percentage of negative mice for each dose 
of cells. Solid lines indicate the best-fit linear model for each data set. 
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Collectively, I demonstrated that heterozygote p53R248W mutant increases 
the competitive advantage of HSCs but does not affect terminal differentiation in 
vivo.  
5. GOF mutant p53 does not affect HSC Homing 
Increased repopulating potential of p53R248W/+ HSCs in transplantation 
assays may due to enhanced homing capability. Therefore, I performed homing 
assays to evaluate the homing capability of p53R248W/+ HSCs. Briefly, bone 
marrow cells (CD45.2+) from either p53+/+ or p53R248W/+ mice were ex vivo-labeled 
with CFSE and injected into lethally irradiated recipient mice. 18hrs after 
transplantation, bone marrow cells of recipient mice were analyzed by flow 
cytometry. I found that there was no difference on the percentage of CD45.2+ BM 
cells and CD45.2+ HSCs (Lin-Sca-1+CD48-CD150+) in the recipient mice 
repopulated with p53R248W/+ BM cells compared to those of p53+/+ BM cells 
(Figures 3.9.A and 3.9.B). Thus, mutant p53 does not affect HSC homing.  
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Figure 3.9 Mutant p53 does not affect HSC homing. 
(A)  1 x 107 bone marrow cells (CD45.2+) from p53+/+ and p53R248W/+ mice 
were transplanted into lethally irradiated recipient mice (CD45.1+). At 18 
hours after transplantation, the percentage of donor-derived cells in the 
bone marrow of recipient mice was determined by flow cytometry. n=7 
mice per group. 
(B) The frequency of donor-derived LSKs in the bone marrow of recipient 
mice 18 hours after transplantation was determined by flow cytometry. n=7 
mice per group. 
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Conclusion and Discussion (Chapter Three) 
GOF TP53 mutations have been found in the blood of aged healthy 
individuals as well as in patients with MDS, implying their important role in clonal 
hematopoiesis and pre-leukemic HSC development (Genovese et al., 2014). In 
this study, I analyzed HSC behavior in young adult p53+/+ and p53R248W/+ mice 
and discovered that heterozygote mutant p53 enhances the repopulating 
potential of HSCs without affecting terminal differentiation. Further, I found that 
GOF mutant p53 does not affect the quiescence, survival, and homing of HSCs.  
Previously, we have reported that p53 knockout (KO) mice have an 
increase number of proliferating HSCs (Liu et al., 2009b), demonstrating the 
importance of p53 in regulating p53 quiescence. Given that the majority of 
missense TP53 mutations are located at the DNA-binding domain (DBD) of p53 
protein, its sequence-specific DNA-binding activity may be altered (Brosh et al., 
2009), which may acquire “gain-of-function” (GOF) properties in human cancer 
(Song et al., 2007; Brosh et al., 2009). Here, I speculated that GOF mutant p53 
proteins have distinct biological impact on HSCs in comparison to the effect of 
p53 loss. Indeed, I found that p53+/+ and p53R248W/+ mice had similar numbers of 
LT-HSCs (Figure 3.2.C) and heterozygote mutant p53 does not affect HSC 
quiescence (Figure 3.4.B). These findings suggest that p53R248W mutant is not a 
loss-of-function mutant.           
In an effort to examine the role of mutant p53 on HSC self-renewal, I 
performed in vivo transplantation in completive settings and discovered that 
p53R248W mutant enhanced repopulating potential of HSCs without affect terminal 
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differentiation. Furthermore, limiting dilution transplantation assays revealed that 
there are more functional HSC in p53R248W/+ mice compared to p53+/+ mice. In 
addition, I demonstrated that the enhanced repopulating potential of mutant 
HSCs in transplantation assay is not due to increased homing capability. Taken 
together, these results demonstrate that HSCs harboring TP53 mutations 
outcompete wild type HSCs to drive clonal expansion.        
Pre-leukemic HSCs have increased competitive advantage allowing clonal 
expansion (Corces-Zimmerman et al., 2014; Shlush et al., 2014). Meanwhile, 
Pre-leukemic HSCs maintain normal hematopoietic differentiation (Corces-
Zimmerman et al., 2014; Shlush et al., 2014). Given that HSCs expressing 
mutant p53 recapitulate these two key features of pre-leukemic HSCs in steady 
state, I conclude that p53R248W mutant drives the development of pre-leukemic 
HSCs. 
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CHAPTER FOUR 
GOF mutant p53 protects HSCs from genotoxic stress and promotes their 
clonal expansion 
Introduction 
p53 plays a pivotal role in regulating cell cycle arrest, DNA damage repair, 
apoptosis, and senescence in response to genotoxic stress (Bálint et al., 2001; 
Brown et al., 2009). Loss of p53 decreases cell apoptosis induced by genotoxic 
stress (Mihara et al. 2003; Brown et al., 2009). Previously, we have 
demonstrated that p53 promotes DNA damage repair in HSCs under genotoxic 
stress (Liu et al., 2009b). We found that p53 and MEF double knock-out HSCs 
have more r-H2AX foci, a DNA damage indicator, than MEF-deficient HSCs 
following irradiation (Liu et al., 2009b). p53-null HSCs are resistant to 
chemotherapeutic agents treatment and show enhanced repopulation potential 
following chemotherapy compared to WT HSCs (Shounan et al., 1996; Park et 
al., 2003; Liu et al., 2009a). These studies suggest that p53 sensitizes HSCs to 
genotoxic stress.  
Pre-leukemic HSCs are resistant to chemotherapy and frequently 
progress to leukemia stem cells (LSCs) under stress conditions (Corces-
Zimmerman et al., 2014; Shlush et al., 2014), thereby serving as a reservoir for 
disease relapse. I found that mutant p53 enhances repopulation potential of 
HSCs and drives the development of pre-leukemic HSCs. However, whether 
HSCs expressing mutant p53 are resistance to irradiation and chemotherapy 
treatment is largely unknown. I hypothesized that mutant p53 preserves HSC 
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function in response to genotoxic stress and promotes clonal expansion of 
HSCs under stress conditions.     
To test my hypothesis, I first challenged p53+/+ and p53R248W/+ mice with 
9Gy total body irradiation (TBI) and monitored their survival. I then examined the 
survival of HSCs after exposing to low dose irradiation. r-H2Ax staining was  
performed to assess the sensitivity of mutant HSCs to DNA damages. To 
evaluate the effect of irradiation on HSC function, I performed serial competitive 
transplantation of BM cells isolated from irradiated p53+/+ and p53R248W/+ mice. I 
predicted that HSCs expressing mutant p53 are not sensitive to irradiation and 
mutant p53 preserves HSC functions.           
I next investigated whether HSCs expressing mutant p53 are resistant to 
chemotherapy. I employed weekly 5-FU treatment to p53+/+ and p53R248W/+ mice 
and recorded their survival. I also monitored hematopoietic recovery of p53+/+ 
and p53R248W/+ mice after one-dose 5-FU injection by examining white blood cell 
counts. In addition, I assessed the apoptosis of p53+/+ and p53R248W/+ HSCs 
following 5-FU treatment. Further, I calculated the absolute number of total bone 
marrow cells and HSCs from p53+/+ and p53R248W/+ mice 7 days after a single-
dose 5-FU administration. In order to assess the function of mutant HSCs after 
chemotherapy, I performed competitive transplantation assays using BM cells 
from 5-FU treated p53+/+ and p53R248W/+ mice. I predicted that HSCs expressing 
mutant p53 are resistant to chemotherapy and maintain their repopulating 
potential in vivo. 
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Finally, I performed clonal expansion experiments by transplanting BM 
cells consisting CD45.1+ p53+/+ and CD45.2+ p53R248W/+ cells at a ratio of 10:1 
into lethally irradiated recipient mice. Irradiation or chemotherapeutic drug ENU 
were applied to recipient mice 8-week post transplantations. The engraftment of 
p53R248W/+ BM cells were examined 16-week after treatment. I predicted that 
mutant p53 promotes clonal expansion of hematopoietic cells in recipient mice 
after irradiation or chemotherapy. The objective of this study was to investigate 
the biological impact of genotoxic stress on mutant p53 HSC function.  
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Results 
1. Mutant p53 HSCs are not sensitive to irradiation 
p53 plays important role in response to irradiation (Bálint et al., 2001; 
Brown et al., 2009). While p53 null HSCs are resistant to irradiation (Liu et al., 
2009), the response of HSCs expressing mutant p53 to irradiation is largely 
unknown. Thus, I investigated the impact of GOF mutant p53 on HSC function 
flowing irradiation. I challenged p53+/+ and p53R248W/+ mice with 9Gy total body 
irradiation (TBI) and found that all p53+/+ mice died 5 weeks following 9Gy TBI, 
whereas 90% of p53R248W/+ mice were still alive (Figure 4.1.A). I then examined 
the survival of mutant p53 HSCs following irradiation. I first irradiated p53+/+ and 
p53R248W/+ mice at dose of 2Gy and then isolated HSCs from the mice 2hrs after 
irradiation and assessed for apoptosis. As shown in Figure 4.2.B, p53R248W/+ 
HSCs and HSPCs show decreased apoptosis compared to p53+/+ cells. When I 
irradiated freshly isolated HSCs, I found that p53R248W/+ HSCs showed decreased 
apoptosis 2hrs after irradiation (Figures 4.1.C). Using phosphorylation of histone 
H2AX (γH2AX) as an indicator of DNA damage, I found that p53R248W/+ HSCs 
were largely devoid of γH2AX foci, whereas p53+/+ HSCs stained positive for 
γH2AX following irradiation. (Figures 4.1.D and 4.1.E). These findings 
demonstrate that HSCs expressing mutant p53 are less sensitive to irradiation. 
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Figure 4.1 HSCs expressing mutant p53 are less sensitive to 
irradiation. 
(A)  Kaplan-Meier survival curve of p53+/+ and p53R248W/+ mice after 9 Gy 
total body irradiation (TBI). ***p<0.001, n = 10 mice per group.  
(B) Hematopoietic stem and progenitor cells from the BM of p53+/+ and 
p53R248W/+ mice were assessed for apoptosis 2 hours after 2Gy irradiation. 
n = 3 mice per group, **p<0.01. 
(C) HSCs from the BM of p53+/+ and p53R248W/+ mice treated with 2 Gy TBI 
were assessed for apoptosis. n = 3 mice per group, *p<0.05. 
(D) Fluorescence intensity of γ-H2AX in LT-HSCs at 4 hours after 2 Gy 
irradiation was determined by ImageStream flow cytometry. 
(E) γ-H2AX foci generation in HSCs following irradiation. LT-HSCs from 
p53+/+ and p53R248W/+ mice were immunostained for γ-H2AX at 4 hours 
after 2 Gy irradiation. LT-HSCs were stained with DAPI to identify the 
nuclei. 
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2. Mutant p53 maintains HSC function following irradiation 
To determine the impact of irradiation on p53R248W/+ HSC function in vivo, I 
first treated p53+/+ and p53R248W/+ mice with 2 Gy TBI and then isolated BM cells 
from irradiated mice for competitive transplantation assays. Irradiated p53R248W/+ 
BM cells displayed enhanced repopulating potential in both primary and 
secondary transplantation assays compared to irradiated p53+/+ BM cells 
(Figures 4.2.A and 4.2.E). I observed increased frequency of hematopoietic stem 
and progenitor cells in the bone marrow of primary recipient mice repopulated 
with irradiated p53R248W/+ BM cells (Figures 4.2.C and 4.2.D). While p53R248W/+ 
had no effect on multi-lineage differentiation of HSCs and progenitors in 
peripheral blood of primary recipient mice (Figure 4.2.B), I found decreased 
myeloid differentiation and increased B cell differentiation in the secondary 
recipient mice repopulated with p53R248W/+ BM cells compared to p53+/+ BM cells 
(Figure 4.2.F).  
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Figure 4.2 Mutant p53 maintains the repopulating potential of 
irradiated hematopoietic stem cells in serial competitive bone marrow 
transplantation assays. 
(A)  The percentage of donor-derived cells in PB of primary recipient mice. 
n=7 mice per group. ****p<0.001 n = 7 mice per group, *p<0.05, 
***p<0.001, ****p<0.0001. 
(B) The percentage of donor-derived myeloid cells, B cells, and T cells in 
peripheral blood of the primary recipient mice 16 weeks following 
transplantation. n = 7 mice per group. 
(C) The percentage of donor-derived LT-HSCs, ST-HSCs, MPPs, and LSK 
cells in the bone marrow of primary recipient mice 16 weeks following 
transplantation was determined by flow cytometry analysis. n = 7 mice per 
group, ***p<0.001. 
(D) The percentage of donor-derived MEPs, CMPs, and GMPs in the bone 
marrow of primary recipient mice 16 weeks following transplantation was 
determined by flow cytometry analysis. n = 7 mice per group, ***p<0.001. 
(E) The percentage of donor-derived cells in PB of secondary recipient 
mice. n=7 mice per group. ****p<0.001 
(F) The percentage of donor-derived myeloid cells, B cells and T cells in 
peripheral blood of the secondary recipient mice 16 weeks after 
transplantation. n = 7 mice per group, ***p<0.001, ****p<0.0001. 
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3. Mutant p53 HSCs are not sensitive to chemotherapy 
To investigate whether HSCs expressing mutant p53 are chemo-resistant, 
I challenged p53+/+ and p53R248W/+ mice with weekly 5-FU treatment and found 
that more than 80% of the p53+/+ mice died within 7 weeks, whereas all of the 
p53R248W/+ mice survived, suggesting that p53R248W/+ mice were resistance to 5-
FU treatment (Figure 4.3.A). I next monitored peripheral blood counts of p53+/+ 
and p53R248W/+ mice after a single-dose of 5-FU treatment. p53+/+ mice underwent 
myelosuppression following 5-FU treatment and recovered back to normal 28 
days after treatment (Figure 4.3.B). However, p53R248W/+ mice exhibited a rapid 
recovery with their white blood cell count went above normal level in 10 days 
after 5-FU injection (Figure 4.3.B). I hypothesized that the rapid recovery rate 
was due to decreased apoptosis of mutant hematopoietic cells. Indeed, Annexin 
V/DAPI staining of LT-HSCs after a single-dose of 5-FU treatment revealed that 
p53R248W/+ HSCs were less apoptotic following 5-FU injection (Figure 4.3.A). I 
also observed increased bone marrow cellularity and increased number of LT-
HSCs in p53R248W/+ mice 7 days after 5-FU administration compared to p53+/+ 
mice (Figure 4.3.D, 4.3.E and 4.3.F). 
To examine the functional impact of chemotherapy on mutant p53 HSCs, I 
isolated bone marrow cells from 5-FU treated p53+/+ and p53R248W/+ mice and 
then performed competitive transplantation assay. I found that p53R248W/+ BM 
cells showed enhanced reconstitution capability compared to p53+/+ BM cells 16-
week post transplantation, manifested by increased percentage of donor-derived  
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mutant cells in PB of recipient mice (Figure 4.3.G). However, mutant p53 did not 
affect terminal differentiation in the PB of recipient mice (Figure 4.3.H). 
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Figure 4.3 HSCs expressing mutant p53 are less sensitive to 5-FU 
administration. 
(A)  Kaplan-Meier survival curve of p53+/+ and p53R248W/+ mice after weekly 
5-FU administration. n = 10 mice per group. ***p<0.001. 
(B)  White blood cell counts of p53+/+ and p53R248W/+ mice after single-dose 
5-FU treatment. n = 7 mice per group, *p<0.05, **p<0.01, ***p<0.001. 
(C)  Percentage of early apoptotic cells in p53+/+ and p53R248W/+ HSCs after 
single-dose 5-FU treatment. n = 3 mice per group, **p<0.01. 
(D)  Bone marrow cellularity of p53+/+ and p53R248W/+ mice 7 days after 
single-dose 5-FU treatment. n = 5 mice per group, ***p<0.001. 
(E)  Frequency of HSCs in the BM of p53+/+ and p53R248W/+ mice 7 days 
after single-dose 5-FU treatment. n = 5 mice per group, *p<0.05. 
(F)  Absolute number of HSCs in the BM of p53+/+ and p53R248W/+ mice 7 
days after single-dose 5-FU treatment. n = 5 mice per group, **p<0.01. 
(G)The frequency of donor-derived cells in PB of primary recipient mice. 
n=7 mice per group. n = 7 mice per group, **p<0.01, ***p<0.001. 
(H) The frequency of donor-derived myeloid cells, B cells, and T cells in 
peripheral blood of the primary recipient mice 16 weeks following 
transplantation. n = 7 mice per group. 
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4. Mutant p53 promotes clonal expansion of hematopoietic cells following 
genotoxic stress 
To determine whether functional GOF TP53 mutation promotes HSC 
expansion following genotoxic stress, I generated mixed BM chimaeras 
containing both p53+/+ and p53R248W/+ cells with a 10:1 ratio of p53+/+ cells (CD45. 
1+) to p53R248W/+ cells (CD45.2+). Eight weeks following transplantation, recipient 
mice were treated with DMSO, chemotherapeutic drug ENU, or 5 Gy TBI (Figure 
4.5.A). p53R248W/+ HSCs outcompeted p53+/+ cells, and underwent clonal 
expansion following total body irradiation or ENU treatment (Figure 4.5.B). In 
addition, total body irradiation treatment significantly increased frequency of 
p53R248W/+ HSCs in the BM of recipient mice (Figure 4.5.C). Thus, mutant p53 
protects HSCs from genotoxic stress and promotes their clonal expansion. 
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Figure 4.4 Mutant p53 promotes clonal evolution of HSCs under 
genotoxic stress in vivo. 
(A)  Bone marrow chimaeras were generated by transplanting a 10:1 ratio 
of p53+/+ cells (CD45. 1+) to p53R248W/+ cells (CD45.2+) into irradiated 
recipient mice (CD45.1+CD45.2+). After hematopoietic reconstitution (8 
weeks), mice were treated with DMSO, ENU or 5Gy TBI. 
(B) Frequency of p53R248W/+ (CD45.2+) cells in the peripheral blood of 
recipient mice following DMSO, ENU, or TBI treatment. n = 7 or 8 mice per 
group, ***p<0.001.  
(C) Frequency of p53R248W/+ LSK cells (CD45.2+) in the peripheral blood of 
recipient mice following DMSO, ENU, or TBI treatment.  n = 7 or 8 mice 
per group, **p<0.01. 
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Conclusion and Discussion (Chapter Four) 
In this study, I demonstrated that mutant p53 protects HSCs from 
genotoxic stress and promotes their clonal expansion. These results recapitulate 
one of the key features of pre-leukemic HSCs, which is chemo-resistance 
(Corces-Zimmerman et al., 2014; Shlush et al., 2014). Therefore, this study 
provides additional evidence to support my conclusion that mutant p53 drives the 
development of pre-leukemic HSCs. 
Tumor suppressor p53 is the guardian of the genome (Bálint et al., 2001; 
Brown et al., 2009). In response to stress signals, such as oncogene activation, 
DNA damage or hypoxia, p53 is activated, triggering cell cycle arrest, DNA 
damage repair, senescence or apoptosis (Bálint et al., 2001; Mihara et al. 2003; 
Brown et al., 2009). We have reported that p53 promotes DNA damage repair in 
HSCs following irradiation and p53-null HSCs are resistant to genotoxic stress 
manifested by decreased apoptosis (Liu et al., 2009). These studies identified a 
critical role for p53 in HSCs under stress conditions. Here, I found that mutant 
HSCs were less apoptotic than WT HSCs in response to low dose irradiation. 
Moreover, there were less γH2AX foci formation in p53R248W/+ HSCs compared to 
p53+/+ HSCs. These findings demonstrate that HSCs expressing mutant p53 are 
less sensitive to irradiation. Furthermore, serial competitive transplantation 
assays using BM cells isolated from irradiated p53+/+ and p53R248W/+ mice 
revealed that p53R248W/+ bone marrows show enhanced repopulating potential 
compared to that of p53+/+bone marrow cells, suggesting that mutant p53 
preserves HSC function following irradiation.  
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p53 affects the proliferation and exhaustion of hematopoietic stem and 
progenitor cells in the bone marrow after 5-FU treatment (Shounan et al., 1996; 
Park et al., 2003; Liu et al., 2009a). Here, I observed that mutant p53 facilitated 
the regeneration of hematopoietic systems after myelosuppression caused by 5-
FU treatment. This effect was due to decreased apoptosis of HSCs bearing p53 
mutation. I also found that the pool of HSCs in p53R248W/+ bone marrow was 
exhausted more slowly than that of the p53+/+ bone marrow following 5-FU 
treatment. These results suggest that HSCs bearing p53 mutation are less 
sensitive to chemotherapy and mutant p53 promotes hematopoietic regeneration 
after chemotherapy treatment. Further, competitive transplantation of BM from 5-
FU treated p53+/+ and p53R248W/+ mice showed that p53R248W/+ bone marrow cells 
show enhanced engraftment in lethally irradiated recipients compared to 
p53+/+bone marrow cells, suggesting that mutant p53 preserves HSC function in 
response to chemotherapeutic agents.  
Finally, clonal expansion experiments under stress conditions indicate that 
mutant p53 promotes clonal expansion of HSCs in response to genotoxic stress. 
These results suggest that AML and MDS patients with TP53 mutations should 
not be treated with conventional chemotherapy and radiotherapy. Collectively, 
my findings demonstrate that mutant p53 protects HSCs from genotoxic stress, 
thereby promoting the clonal expansion of pre-leukemic HSCs. These studies 
underscore the importance of developing novel therapeutic approaches to target 
chemotherapy and irradiation resistant pre-leukemic HSCs bearing TP53 
mutations. 
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CHAPTER FIVE 
Aged heterozygous mutant p53 mice develop MDS 
Introduction 
While the roles of mutant p53 in oncogenesis of solid tumors have been 
well delineated, its functional impact on myeloid malignancies remains elusive. 
Myelodysplastic syndrome (MDS) is a heterogeneous group of disease 
characterized by dysplastic hematopoietic cells, peripheral blood cytopenia and 
high risk of progression to AML (Nimer, et al. 2008; Sperling, et al. 2017; Woll, et 
al. 2014). Although progress has been made on MDS treatment, the clinical 
outcome of MDS patients is still very poor (Sperling, et al. 2017). TP53 mutations 
present in 10% of primary MDS, and characterized by severe thrombocytopenia, 
elevated blast count and complex karyotypes (Rücker, et al. 2012; Sperling, et al. 
2017). Moreover, TP53 mutations are associated with drug resistance and 
shortest survival (Chang, et al. 2017; Volkert, et al. 2014; Welch, et al 2016). 
Allogenic bone marrow transplantation does not improve the outcome of MDS 
patients with TP53 mutations due to increased relapse post-transplantation 
(Christopeit, et al. 2016; Lindsley, et al. 2017). Notably, the frequency of TP53 
mutations increases to a large extent after patients are exposed to irradiation or 
alkylating agents (Metzgeroth, et al. 2016). Despite the clinical importance of 
TP53 mutations in MDS, little is known regarding how these mutations contribute 
to the development of MDS. Therefore, it is of great importance to advance our 
understanding of the role of TP53 mutations in the pathogenesis of MDS. 
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MDS is not easy to study in the laboratory due to the difficulty of engrafting 
human MDS in immunodeficient mice (Rhyasen, et al. 2014). Meanwhile, lack of 
proper MDS murine models increases the challenge of studying the disease 
development (Zhou, et al, 2015). It has been evaluated that most p53-/- and 
p53R248W/R248W mice develop spontaneous tumors, including lymphoma, 
thymoma, and sarcoma, and die within 3 to 6 months after birth (Song et al., 
2007); whereas disease spectrums of p53R248W/+ mice is not clear. Actually, TP53 
deletions are mainly found in advanced phases of hematological malignancies 
(Harutyunyan, et al. 2011, Rücker, et al. 2012). Importantly, most TP53 
mutations identified in AML or MDS are mono-allele missense mutations having 
gain-of-function properties that promote tumorigenesis (Peller, et al. 2003). 
Therefore, p53-/- and p53R248W/R248W mice are not good models for studying the 
pathogenesis of MDS. Thus, I speculated that p53R248W/+ mice may develop 
different disease spectrums compared to p53-/- and p53R248W/R248W mice. I 
hypothesized that p53R248W/+ mice develop features recapitulating human 
MDS during aging. 
To investigate the role of mutant p53 in the pathogenesis of MDS, I first 
maintained the secondary recipient mice repopulated with p53+/+ and p53R248W/+ 
BM cells for 48 weeks and examined their multi-lineage differentiation ability in 
the PB of recipient mice. Given that mutant p53 causes genome instability, I 
expected to observe impaired lineage differentiation over time in recipient mice 
repopulated with p53R248W/+ BM cells. Next, I monitored the survival and disease 
development of p53+/+ and p53R248W/+ mice during ageing. Peripheral blood, 
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tumor or organs relevant to hematopoiesis, such as bone marrow, spleen, 
thymus and liver, were isolated for pathological analysis. I predicted that 
p53R248W/+ mice develop MDS-like disease that mimics human conditions. The 
objective of the study is to determine the role of mutant p53 in the development 
of MDS.  
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Results 
1. Mutant p53 alters terminal differentiation during aging 
In Chapter Three, I found that mutant p53 does not affect multi-lineage 
differentiation in the PB of both primary and secondary recipient mice after 
competitive BM transplantation, demonstrating that HSCs expressing mutant p53 
retain normal differentiation capabilities. However, the impact of mutant p53 on 
HSC differentiation during aging is largely unknown. 
To determine the impact of mutant p53 on terminal differentiation during 
aging, I maintained the recipient mice from the secondary competitive bone 
marrow transplantation experiments (describe in Chapter Three) for 48-weeks. 
p53R248W/+ BM cells still retained enhanced engraftmentability in the peripheral 
blood compared to p53+/+ BM cells. Strikingly, I observed an decrease of myeloid 
cells (Gr1+) and increase of B lymphoid cells (B220+) in the PB of recipient mice 
repopulated with p53R248W/+ BM cells compared to those of p53+/+ BM cells, 
suggesting that mutant p53 impaired myeloid differentiation over time. These 
results indicate that GOF mutant p53 may predispose mice to MDS development 
during aging. 
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Figure 5.1 Mutant p53 impairs multi-lineage differentiation during 
ageing. 
(A)  Percentage of donor-derived cells in PB of secondary recipient mice 
repopulated the p53+/+ and p53R248W/+ BM. n=7 mice per group, ***p<0.001. 
(B) The frequency of donor-derived myeloid cells, B cells, and T cells in 
peripheral blood of the secondary recipient mice 16 weeks following 
transplantation. n = 7 mice per group. *p<0.05, **p<0.01. 
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2. Characterize aged heterozygous mutant p53 mice 
To evaluate the role of GOF mutant p53 in the pathogenesis of myeloid 
malignancies, I maintained p53+/+ and p53R248W/+ mice till their death to monitor 
their survival rate and tumor development. I observed that p53R248W/+ mice have a 
median age of 18-month-old (Figure 5.2.A), which is much longer than p53-/- and 
p53R248W/R248W mice. I measured peripheral blood cell counts and performed 
peripheral blood smear before their death. I also harvested, organs, including 
bone, spleen, liver, kidney, lung and tumors for H&E staining. Pathology analysis 
revealed that approximately 30 % of p53R248W/+ mice developed MDS (Figure 
5.2.B). Other aged p53R248W/+ mice developed MDS/lymphoma, MDS/sarcoma, 
lymphoma, and sarcoma (Figure 5.2.B); whereas most of the aged-matched 
p53+/+ mice were normal. Thus, p53R248W/+ mice developed different diseases 
compared to p53-/- and p53R248W/R248W mice. 
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Figure 5.2 Survival rate and disease spectrum of aged p53R248W/+ 
mice. 
(A)  Kaplan-Meier survival curve of p53+/+ and p53R248W/+ mice. n=12-15 
mice per group, ***p<0.001. 
(B) p53R248W/+ mice developed various diseases during aging. Disease 
types and frequencies were shown.   
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3. Some aged heterozygous mutant p53 mice developed MDS 
Histological assessment revealed hypercellular BM in some aged 
p53R248W/+ mice (Figure 5.3.A). p53R248W/+ mice also show splenomegaly with 
enlarged spleen and increased spleen weight (Figures 5.3.B and 5.3.C). Indeed, 
hypercellular spleens were found in p53R248W/+ mice compared to p53+/+ mice 
(Figure 5.3.D). Moreover, the spleens of aged p53R248W/+ mice have increased 
numbers of hematopoietic stem and progenitor cells, indicating extramedullary 
hematopoiesis (EMH) in the spleen of mutant mice (Figure 5.3.E).  
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Figure 5.3 Aged p53R248W/+ mice show hypercellular bone marrow and 
extramedullary hematopoiesis in spleen. 
(A)  H&E staining of bone marrow sections from aged p53+/+ mice and aged 
p53R248W/+ mice. 
(B) Representative images of spleens from aged p53+/+ mice and aged 
p53R248W/+ mice.   
(C) Spleen weight of aged p53+/+ mice and aged p53R248W/+ mice.  n = 6 
mice per group, ***p<0.001. 
(D) H&E staining of spleen sections from aged p53+/+ mice and aged 
p53R248W/+ mice. 
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Furthermore, BM of some aged p53R248W/+ mice show neutrophil, erythroid 
precursor and megakarocyte dysplasia (Figure 5.4.A). p53R248W/+ peripheral 
blood smears revealed hypersegmented neutrophils, Pseudo-Pelger-Huet, 
nucleated red cells, and tear-drop red cells (Figure 5.4.B). Significant leukopenia 
and thrombocytopenia were seen in aged p53R248W/+ mice with MDS compared to 
age-matched p53+/+ mice (Figure 5.4.C and 5.4.D). In addition, mild but 
significant anemia was detected in aged p53R248W/+ mice with MDS, manifested 
by low red blood cell counts and decreased levels of hemoglobin (Figure 5.4.E 
and 5.4.F). However, the mean corpuscular volume (MCV) of red blood cells was 
normal (Figure 5.4.G).  
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Figure 5.4 Aged heterozygous mutant p53 mice developed MDS. 
(A) H&E-stained BM sections from p53R248W/+ mice developed MDS. 
Representative images show binucleated myeloid precursor (a, b), 
karyorrhexis in erythroid precursors (c), erythroid precursors with nuclear 
budding (d), binucleated erythroid precursor (e), a giant megakaryocyte (g) 
in comparison to a megakaryocyte from age-matched p53+/+ mice (f).  
(B) Giemsa-stained peripheral blood smears from p53R248W/+ mice 
developed MDS. Representative images show Pseudo-Pelger-Huet (a), 
hypersegmented neutrophil (b), Howell-Jolly body in red blood cells 
(RBCs) (c), polychromatophilic RBCs (d, e), tear-drop RBCs (e).  
(C) White blood cell (WBC) counts in the peripheral blood of p53R248W/+ 
mice developed MDS and age-matched p53+/+ mice. n=6 mice per group, 
***p<0.001. 
(D) Platelet counts in the peripheral blood of p53R248W/+ mice developed 
MDS and age-matched p53+/+ mice. n=6 mice per group, **p<0.01. 
(E) Red blood cell (RBC) counts in the peripheral blood cells of p53R248W/+ 
mice developed MDS and age-matched p53+/+ mice.  n=6 mice per group, 
**p<0.01. 
(F) Hemoglobin (Hb) levels in the peripheral blood cells of p53R248W/+ mice 
developed MDS and age-matched p53+/+ mice.  n=6 mice per group, 
**p<0.01. 
(G) MCV of red blood cells of aged p53+/+ mice and p53R248W/+ mice 
developed MDS. n=6 mice per group, p>0.05, n.s. 
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4. Mutant p53-driven MDS is transplantable 
MDS is a clonal disease originated from mutated MDS stem cells (Nimer, 
et al. 2008; Sperling, et al. 2017). Thus, recipient mice repopulated with bone 
marrow cells from MDS mice might develop MDS over time.  To determine 
whether mutant p53-driven MDS is transplantable, I injected whole BM cells from 
aged wild-type mice and p53R248W/+ mice with MDS into lethally–irradiated 
recipient mice. I found that recipient mice repopulated with MDS BM cells died 
within 24 weeks, whereas no mice transplanted with aged p53+/+ BM cells died 
during observation period (Figure 5.5.A). Furthermore, recipient mice 
repopulated with MDS cells show decreased WBC and RBC counts compared to 
that of the aged p53+/+ cells (Figure 5.5.B and 5.5.C). Importantly, pathology 
analysis of the dead mice revealed MDS and bone marrow failure (Figure 5.5.D), 
suggesting that the MDS phenotype-induced by GOF mutant p53 was 
transplantable. Therefore, I demonstrated that some aged p53R248W/+ mice 
developed MDS, recapitulating several key features of human MDS. 
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Figure 5.5 Mutant p53 driven MDS is transplantable. 
(A) Kaplan-Meier survival curve of recipient mice repopulated with BM cells 
from aged p53+/+ mice or p53R248W/+ mice with MDS. n=6 mice per group, 
**p<0.01. 
(B) Recipient mice developed MDS and bone marrow failure following 
transplantation of BM cells isolated from p53R248W/+ mice with MDS. n = 6 
mice.   
(C) WBC counts in the peripheral blood of recipient mice following BM 
transplantation. n=5 mice per group, ***p<0.001. 
(D) RBC counts in the peripheral blood of recipient mice following BM 
transplantation. n=5 mice per group, ***p<0.001. 
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Conclusion and Discussion (Chapter Five) 
TP53 mutations are present in 10% of primary MDS patients, who have 
severe thrombocytopenia, elevated blast count and complex karyotypes (Rücker, 
et al. 2012; Sperling, et al. 2017). Genetic studies identified TP53 mutations as 
one of the common recurrent lesions in clonal hematopoiesis (Genovese, et al. 
2014; Jaiswal, et al. 2014), implicating a role for TP53 mutations in early steps of 
MDS development. However, how these mutations contribute to MDS and 
whether they are sufficient to drive MDS development is poorly understood. In 
this study, I observed that aged p53R248W/+ mice developed features recapitulating 
human MDS, demonstrating that GOF mutant p53 drives MDS development.  
I have demonstrated that p53R248W is a pre-leukemic mutation driving the 
development of pre-leukemic HSCs without affecting normal differentiation (date 
shown in Chapter Three and Chapter Four).  Given that p53 is the guardian of 
the genome (Brown, et al. 2009; Liu, et al. 2009a), mutations on p53 may lead to 
genome instability, resulting in ineffective hematopoiesis over time. I then 
monitored secondary recipient mice repopulated with p53+/+ and p53R248W/+ BM 
cells for 48 weeks and examined their multi-lineage differentiation in the PB of 
recipient mice. Interestingly, I observed that p53R248W mutant altered terminal 
differentiation over time, manifested by decreased myeloid differentiation and 
increased lymphoid differentiation compared to WT group. Thus, I demonstrated 
that GOF mutant p53 inhibits myeloid differentiation during ageing.   
Next, I monitored the survival and disease development of p53+/+ and 
p53R248W/+ mice. p53R248W/+ mice had a median survival rate of 16 months, which 
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is much longer than what has been reported for p53-/- and p53R248W/R248W mice (3-
6 months old). Strikingly, 30% of p53R248W/+ mice developed features of human 
MDS, including cytopenia, thrombocytopenia, anemia and multi-lineage dysplasia 
in bone marrow cells and peripheral blood (Harutyunyan, et al. 2011, Rücker, et 
al. 2012). Furthermore, transplantation of bone marrow cells from MDS mice 
resulted in lethal MDS or bone marrow failure in lethally irradiated recipient mice, 
suggesting that mutant p53 induced MDS is transplantable. Collectively, these 
results demonstrated that GOF mutant p53 drives the pathogenesis of MDS in 
mice. 
In addition, I observed that some p53R248W/+ mice display lymphoma, 
sarcoma, and mixed disease with lymphoma and MDS. These phenomenon 
were consistent with what have been reported in human cases with heterozygote 
TP53 mutations. Current studies suggest that pre-leukemic state may exist in 
both myeloid and lymphoid malignancies, and diverse diseases may carry the 
same recurrent mutation (Corces-Zimmerman, et al. 2014). My findings that 
p53R248W/+ mice developed different hematological malignancies highlighted the 
clinical importance of eliminating pre-leukemic HSCs harboring TP53 mutations. 
TP53 mutations are associated with drug resistance and dismal prognosis 
in MDS (Chang, et al. 2017; Volkert, et al. 2014; Welch, et al 2016). Allogenic 
bone marrow transplantation does not improve the outcome of MDS patients with 
TP53 mutations due to increased relapse post-transplantation (Christopeit, et al. 
2016; Lindsley, et al. 2017). Our humanized p53R248W/+ mice developing MDS will 
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be a valuable tool to test therapeutic agents for the prevention and treatment of 
MDS patients with TP53 mutations. 
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CHAPTER SIX 
GOF mutant p53 drives pre-leukemic stem cell development through 
regulating gene expression  
Introduction 
p53 regulates gene transcription through its DNA-binding domain (DBD) 
(Patricia et al., 2013). Majority of mono-allele missense mutations on the DNA-
binding domain of p53 alter its sequence-specific binding activity, leading to 
distinct gene expression patterns compared to WT p53 (Brosh et al., 2009). As a 
result, these changes are key mediators of the biological impacts of mutant p53 
on tumorigenesis.  
We have previously identified Gfi-1 and Necdin as p53 target genes in 
HSCs (Liu et al., 2009b). p53 transcriptionally activates both Gfi-1 and Necdin 
genes to maintain HSC quiescence (Liu et al., 2009b). Downregulation of Gfi-1 
and Necdin promote HSC proliferation as seen in p53-null mice (Liu et al., 
2009b). In Chapter Three, I have shown that mutant p53 did not affect HSC 
quiescence, indicating p53R248W is not a loss-of-function mutant. Moreover, I 
demonstrated that p53R248W mutant enhances the competitive advantage of 
HSCs, leading to clonal expansion and the development of pre-leukemic HSCs. 
However, the mechanisms by which mutant p53 drives pre-leukemic HSC 
development remain elusive. I hypothesized that p53R248W enhances HSC self-
renewal through regulating genes or/and pathways important for HSC 
function. 
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To uncover the molecular mechanisms by which mutant p53 drives pre-
leukemic HSCs, I assessed genome-wide changes in the transcriptome by 
performing RNA-seq assay of LSK cells isolated from p53+/+ and p53R248W/+ mice. 
Gene Set enrichment analysis (GSEA) and DAVID analysis were performed to 
examine whether gene signatures or pathways related to HSC regulations were 
altered in p53R248W/+ LSKs compared to p53+/+ LSKs.  
Changes in chromatin accessibility play a critical role in transcriptional 
regulation, reprogramming, and epigenetic controls (Tsompana et al., 2014). 
Chromosome accessibility, reflected by the positioning and distribution of 
nucleosomes throughout a genome, determines the availability of binding regions 
to transcription factors and epigenetic machinery, and affects DNA-dependent 
process such as transcription, thus correlates with gene expression levels 
(Lamparter et al., 2017; Su et al., 2017). Mutant p53 has been shown to execute 
its GOF properties through interacting with transcriptional machineries, activating 
or inhibiting their activity (Brosh et al., 2009; Patricia et al., 2013). Hence, mutant 
p53 may regulate transcription through modulating chromatin accessibility. 
However, this aspect of mutant p53 has not been explored. Therefore, it is 
necessary to determine the state of chromatin accessibility in pre-leukemic HSC 
harboring p53 mutations. I hypothesized that GOF mutant p53 drives the 
development of pre-leukemic HSCs through altering chromatin 
accessibility to genes important for HSC function. 
The Assay for Transposase-Accessible Chromatin with high-throughput 
sequencing (ATAC-seq) is one of the approaches for mapping genome-wide 
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chromatin accessibility (Buenrostro et al., 2013). It utilizes hyperactive Tn5 
transposase to cut and ligate adapters (Goryshin and Reznikoff, 1998; Adey et 
al., 2010). The insertion ends of DNA is then applied to high-throughput 
sequencing allowing for identifying the DNA regions of opened accessibility 
(Buenrostro et al., 2013; Tsompana et al., 2014). I employed ATAC-seq assay to 
compare chromatin accessibility landscape of p53+/+ LSKs and p53R248W/+ LSKs. 
In addition, I searched genome-wide transcription factor binding motifs in mutant 
p53 LSK cells, in an effort to identify transcription factors interacting with mutant 
p53. 
The aim of this study was to elucidate the mechanisms underlying the 
contribution of mutant p53 to pre-leukemic HSC development. This study will 
facilitate the identification of therapeutic targets in pre-leukemic HSCs expressing 
TP53 mutations. 
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Results 
1. GOF mutant p53 HSCs show gene expression signatures important for 
stem cell maintenance and leukemia development 
Mutations on the DNA binding domain of p53 disrupt specific DNA binding 
activity, which may result in loss of wild-type p53 functions (Brosh et al., 2009; 
Patricia et al., 2013). Therefore, I first examined the expression of bona fide wild 
type p53 target genes in HSCs, including p21 and Necdin. As shown in Figure 
6.1.A, HSCs expressing p53R248W does not affect the expression of p21 and 
Necdin, suggesting that p53R248W is not a loss-of-function mutant.  
To identify p53R248W specific target genes in HSC, I utilized RNA-seq 
technique to investigate genome-wide gene expression changes in purified LSKs 
from p53+/+ and p53R248W/+ mice. Computational analysis revealed that 853 genes 
were significantly upregulated and 400 genes were significantly down-regulated 
in p53R248W/+ LSKs compared to p53+/+ LSKs (Figure 6.1.B). I then performed 
Gene Set Enrichment Assays (GESA) analysis to group potential p53R248W target 
genes into specific pathways important for HSC function. I found that HSC 
signatures were significantly enriched in p53R248W/+ LSKs compared to p53+/+ 
LSKs (Figure 6.1.C).  Interestingly, several hematological malignancy signatures, 
including AML, chronic myeloid leukemia (CML), and leukemia stem cell 
signatures, were enriched in p53R248W/+ LSKs compared to p53+/+ LSKs (Figure 
6.1.D). I also performed DAVID pathway analysis and found that several 
pathways important for HSC maintenance, including Regulation of 
Hematopoiesis, Hematopoietic organ development, Immune response, and 
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Positive regulation of cytokine response, were significantly enriched in p53R248W/+ 
LSKs compared to p53+/+ LSKs (Figure 6.1.E).  These findings support my 
hypothesis that mutant p53 drives the development of pre-leukemic HSCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
 
 
 
 
 
 
 
 
 
 
A 
p53+/+
p53R248W/R248W
p53R248W/+
p21 Necdin
0
1
2
R
el
at
iv
e 
m
R
N
A 
ex
pr
es
si
on
B 
C 
D 
NES  1.51
NOM p 0.0
FDR q 0.0
p53R248W/+                    p53+/+ 
NES  1.89
NOM p 0.0
FDR q 0.00016
p53R248W/+                    p53+/+ 
p53R248W/+                   p53+/+ 
NES  0.797
NOM p 
0.80
FDR q 0.80
p53R248W/+                    p53+/+ 
NES  1.09
NOM p 0.32
FDR q 0.32
RNA-seq in LSKs 
p53R248W/+                    p53+/+ 
NES  1.46
NOM p 0.024
FDR q 0.024
NES  1.89
NOM p 0.003
FDR q 0.003
p53R248W/R248W           p53+/+ 
118 
 
 
 
 
 
 
 
 
 
Pathways enriched in  p53R248W/+ HSPCs
Fold enrichment
Figure 6.1 p53R248W/+ HSCs show gene expression signatures 
important for stem cell maintenance and leukemia development  
(A) Quantitative RT-PCR analysis of mRNA levels of p53 target genes, p21 
and Necdin, in HSCs. n=3 biological replicates, p>0.05. 
(B) Number of genes significantly up-regulated or down-regulated in 
p53R248W/+ LSKs compared to p53+/+ LSKs in RNA-seq assays. n=2 
biological repeats, **p<0.01. 
(C) RNA-seq data was applied to Gene Set Enrichment Analysis (GSEA) 
to identify stem cell related gene sets enriched in p53R248W/+ LSKs 
compared to p53+/+ LSKs in molecular signature database (MsigDB). 
(D) GESA analysis showed enrichment of CML, AML and leukemia stem 
cell signatures in p53R248W/+ LSKs compared to p53+/+ LSKs. 
(E) DAVID pathway analysis of genes upregulated in p53R248W/+ LSKs 
compared to p53+/+ LSKs. 
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To rule out the potential dominant-negative (DN) effect of mutant p53 on 
gene expression in HSCs, I performed microarray analysis to compare gene 
expression in HSCs (CD48-CD150+LSKs) isolated from p53+/+ and p53R248W/R248W 
mice. I found that 1, 610 genes were significantly upregulated, and 1,150 genes 
were down-regulated in p53R248W/+ HSCs compared to p53+/+, respectively 
(Figure 6.2.A). GESA analysis indicate that HSC signatures and several 
hematological malignancy signatures, including CML, AML, and poor-prognosis 
AML genes, were enriched in p53R248W/R248W HSCs compared to p53+/+ HSCs 
(Figures 6.2.B and 6.2.C). Taken together, the gene expression profiling data 
provided additional evidence that GOF mutant p53 modulates specific pathways 
associated with hematopoiesis and leukemogenesis, thereby predisposing 
normal HSCs to leukemic transformation.  
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Figure 6.2 p53R248W/R248W HSCs show gene expression signatures 
important for stem cell maintenance and leukemia development  
(A) Number of genes significantly up-regulated or down-regulated in 
p53R248W/R248W HSCs compared to p53+/+ HSCs in microarray assays. n=3 
biological repeats, **p<0.01. 
(B) GESA analysis showed enrichment of HSC signature in p53R248W/R248W 
HSCs compared to p53+/+ HSCs. 
(C) GESA analysis showed enrichment of CML and AML signatures in 
p53R248W/R248W HSCs compared to p53+/+ HSCs. 
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2. GOF mutant p53 alters chromatin accessibility in HSPCs 
Given that p53 functions as a transcription factor binding to chromatin to 
regulate the transcription of its target genes (Brosh et al., 2009; Patricia et al., 
2013), it is possible that GOF mutant p53 may change gene expression through 
altering chromatin accessibility. Therefore, I utilized ATAC-seq assay to identify 
differential regions of chromatin accessibility (Buenrostro et al., 2013) of 
p53R248W/+ LSKs in comparison to p53+/+ LSKs. Approximately 600 peaks were 
significantly upregulated in p53R248W/+ LSKs compared to p53+/+ LSKs (Figure 
6.3.A), and around 600 peaks were significantly downregulated in p53R248W/+ 
LSKs compared to p53+/+ LSKs (Figure 6.3.A). DAVID pathway analysis of the 
ATAC peaks that were significantly upregulated in p53+/+ LSKs revealed 
enrichment in p53 pathway, canonical Wnt signaling, and negative regulation of 
immune system processes (Figure 6.3.B), which is consistent with known p53 
functions. Interestingly, HSC maintenance and HSC self-renewal pathways were 
enriched in p53R248W/+ LSKs (Figure 6.3.C). Additionally, I found that pathways 
related to mRNA splicing and SNF-2 interaction, which have been reported to 
regulate HSC functions, are enriched in in p53R248W/+ LSKs (Figure 6.3.C). 
Furthermore, pathway analysis result revealed that p53R248W may function as 
both transcriptional co-activator and co-repressor in HSPCs. 
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Figure 6.3 Enriched biological processes of genes associated with 
upregulated ATAC-seq peaks in p53+/+ and p53R248W/+ LSKs. 
(A) Heat map of differential active regions in p53R248W/+ and p53+/+ LSKs. 
(B) Enriched biological processes of genes associated with significantly 
upregulated ATAC-seq peaks in p53+/+ LSKs analyzed by DAVID 
Functional Annotation Tool. 
(C) Enriched biological processes of genes associated with significantly 
upregulated ATAC-seq peaks in p53R248W/+ LSKs analyzed by DAVID 
Functional Annotation Tool. 
 
 
124 
3. GOF mutant p53 interacts with transcription factors to regulate 
chromatin accessibility 
Mutant p53 may function as a transcription cofactor in regulating gene 
expression as implicated in Figure 6.3.C. I decided to identify potential 
transcription factors that are associated with mutant p53. I performed motif 
search to analyze the differential accessible peaks in p53+/+ and p53R248W/+ LSK 
cells. I identified strong enrichment for transcription factor (TF) binding sites, 
including CTCF, ETS1, MEIS1, and FOXO1(Figure 6.4), which play important 
roles in hematopoiesis (Degner et al., 2011; Barton et al., 1998; Kocabas et al., 
2012; Tothova et al., 2007). For example, both MESI1 and FOXO1 are critical 
mediators of HSCs via limiting oxidative stress and this preserving HSC 
functions. The motif searching results may provide additional mechanisms by 
which mutant p53 maintains HSC functions. 
 
 
 
 
 
125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meis1      p=1e-2, % target=20.63%
FOXO1     p=1e-2, % target=22.82%
CTCF        p=1e-60, % target=10.52%
ETS1         p=1e-34, % target=10.52%
Figure 6.4 Enrichment of transcription factor motifs in peaks that gain 
open accessibility in p53R248W/+ LSKs compared to p53+/+ LSKs 
determined by HOMER de novo or Known Motif Analysis. 
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4. GOF mutant p53 increases the chromatin accessibility to genes 
important for HSC maintenance 
To identify specific genes with changes in chromatin accessibility upon 
expression of mutant p53, I next wanted to investigate chromatin accessibility 
changes on specific genes regulated by mutant p53. I found that mutant p53 
increased chromatin accessibility to Cxcl9 and Sox2 genes as visualized on 
UCSC Genome browser (Figure 6.5.A). Chemokine gene Cxcl9 has been shown 
to regulate HSPC expansion and protect HSPC from chemotherapy (Broxmeyer 
et al., 2006; Lu, et al., 2012). Sox2 is a pluripotency gene important for stem cell 
maintenance in embryonic stem cells (Takahashi et al., 2006). Upregulation of 
Sox2 has been suggested to be responsible, at least in part, for ex vivo 
expansion of cord-blood CD34+ induced by HADC inhibitor (Chaurasia et al., 
2014), implicating a potential role of Sox2 in HSC clonal expansion. 
By performing qPCR analysis, I validated that both Cxcl9 and Sox2 were 
upregulated in p53R248W/+ LSKs compared to p53+/+ LSKs (Figure 6.5.B). Thus, I 
demonstrate that GOF mutant p53 alters chromatin accessibility to genes 
important for HSC maintenance. 
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Figure 6.5 Expression of Cxcl9 and Sox2 are increased in p53R248W/+ 
HSCs. 
(A) UCSC genome browser tacks of normalized ATAC-seq peaks at the 
TSS region of Cxcl9 and Sox2 genes in p53+/+ and p53R248W/+ LSKs. 
(B) Quantitative RT-PCR analysis of Cxcl9 and Sox2 expression in p53+/+ 
and p53R248W/+ LSKs. n=3 biological replicates, **p<0.01, ***p<0.01. 
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Conclusion and Discussion (Chapter Six) 
In previous chapters, I have demonstrated that mutant p53 enhances the 
repopulating potential of HSCs and promotes their clonal expansion, driving the 
development of pre-leukemic HSCs. I next tried to uncover the molecular 
mechanisms by which mutant p53 promotes pre-leukemic HSC development. In 
this study, I demonstrated that mutant p53 regulates genes or/and pathways 
important for HSC function.  
Mutant p53 may exhibit loss-of-function, dominant-negative effect or gain-
of-function properties in driving tumorigenesis in human cancer (Brosh et al., 
2009; Patricia et al., 2013). p21 is a classic target of p53 in regulating cell cycle 
(Wang et al., 2009). Additionally, we have identified Necdin and Gfi-1 as p53 
target genes in regulating HSC quiescence (Liu et al., 2009b). Loss of p53 leads 
to downregulation of Necdin and Gfi-1 in HSCs (Liu et al., 2009b), resulting in 
decreased number of quiescent HSCs. However, I observed no changes on 
quiescent state between p53+/+ and p53R248W/+ HSCs, ruling out loss-of-function 
effect of mutant p53 on HSCs. To validate the result from the molecular 
perspective, I conducted qPCR assays to examine the expression of bona fide 
p53 targets in HSCs expressing p53R248W. Interestingly, mRNA levels of p21 and 
Necdin were changed in neither p53R248W/+ HSCs nor p53R248W/R248W HSCs, in 
comparison to those of p53+/+ HSCs. These data further demonstrate that mutant 
p53 does not affect HSC quiescence and that p53R248W is not a loss-of-function 
mutant. 
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To further understand how mutant p53 affects transcriptome, I performed 
RNA-seq assays of p53+/+ and p53R248W/+ LSK cells. Comprehensive 
bioinformatic analysis revealed that HSCs harboring p53R258W mutation showed 
enriched HSC signatures as well as leukemic stem cell signatures, consistent 
with my findings that mutant p53 enhances the repopulating potential of HSCs 
and aged p53R248W/+ mice developed MDS. Therefore, results from RNA-seq 
analysis support my conclusion that TP53 mutation is a pre-leukemic mutation 
that predisposes pre-leukemic HSC to leukemic transformation. 
I also performed gene expression profiling assays using p53+/+ and 
p53R248W/R248W LT-HSCs and found that HSC and leukemia stem cell signatures 
were enriched in mutant HSCs. Given that p53R248W/+ HSCs and p53R248W/R28W 
HSCs share similar gene expression profiles compared to WT HSCs, I 
demonstrate that  p53R258W does not have a dominant-negative effect on gene 
expression in HSCs.  
To decipher the gain-of-function mechanisms underlying GOF mutant p53 
on HSC function, I employed ATAC-seq assays to map open chromatin regions 
of pre-leukemic HSCs expressing mutant p53. Comparison of p53+/+ and 
p53R248W/+ LSK cells revealed pathways regulated by wild-type p53 in WT cells 
consistent with published results. For example, pathway related to p53-like 
transcription factor and DNA binding activity were significantly enriched in in 
p53+/+ LSKs. On the contrary, pathways relevant to stem cell maintenance and 
HSC self-renewal were enriched in p53R248W/+ LSK cells, further supporting the 
findings from RNA-seq analysis that mutant p53 contributes to pre-leukemic HSC 
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development through regulating pathways involved in HSC maintenance. 
Interestingly, I also observed pathways related to transcription coactivator 
activity, transcription corepressor activity, and RNA Pol II relevant chromatin 
binding activity were enriched in mutant HSCs, implying a potential role for 
mutant p53 in transcriptional regulation. Moreover, enrichment of spliceosome 
and SWI/SNF related interaction pathways were also found in mutant HSCs. 
Mounting evidence suggest a critical role of spliceosome in normal and malignant 
hematopoiesis (Abdel-Wahab et al., 2011; Lee et al., 2016). Importantly, high 
frequency of spliceosome gene mutations were identified in aged individuals with 
clonal hematopoiesis and in patients with MDS (Yoshida et al., 2011; Inoue et al., 
2016), suggesting that alteration of spliceosome causes hematopoietic disorders. 
SWI/SNF is a chromatin remodeling complex mediating transcriptional machinery 
(Kadoch et al., 2015). GOF mutant p53 associated with SWI/SNF complex in 
breast cancer cells, promoting their tumorigenesis (Pfister et al., 2015). My 
findings that mutant p53 may interfere spliceosome activity and/or associate with 
SWI/SNF complex are intriguing, as that may be novel mechanisms underlying 
the gain-of-function activity of mutant p53 in HSCs. 
Furthermore, ATAC-assay facilitates the discovery of open chromatin 
regions that are occupied by transcription factors (Lamparter et al., 2017; Su et 
al., 2017). By performing comprehensive motif analysis, I was able to identify 
transcription factors that may cooperate with mutant p53 in regulating gene 
expression in HSCs. These transcription factors are CTCF, ETS1, MEIS1 and 
FOXO1, which have been implicated as important regulators in hematopoiesis 
131 
(Degner et al., 2011; Barton et al., 1998; Kocabas et al., 2012; Tothova et al., 
2007). Particularly, MEIS1 and FOXO1 are critical mediators of HSC by limiting 
oxidative stress (Kocabas et al., 2012; Tothova et al., 2007). MEIS1 is required 
for expansion of adult HSC (Kocabas et al., 2012). Deletion of MEIS1 resulted in 
dramatic decrease of repopulating potential of HSCs due to accumulation of 
reactive oxygen species (ROS), demonstrating that MEIS1 preserves HSC 
functions through restricting oxidative stress (Kocabas et al., 2012). FOXO family 
proteins, including FOXO1, FOXO3, FOXO4, are required for HSC long-term 
regenerative potential, as they decrease the accumulation of ROS in HSCs and 
protect HSCs from physiological oxidative stress (Tothova et al., 2007). 
Therefore, my findings that mutant p53 interacts with MEIS1 and FOXO1 may 
help explain how mutant p53 enhances repopulating potential of HSCs in vivo.  
Finally, I found that mutant p53 increases the chromatin accessibility to 
several genes, including Sox2 and Cxcl9. Consistently, the transcription levels of 
these genes were increased in p53R248W/+ LSK cells. CXCL9 is a chemokine that 
regulates HSPC expansion and protect HSPC from chemotherapy treatment 
(Broxmeyer et al., 2006; Lu, et al., 2012). Upregulation of Cxcl9 in mutant HSCs 
may provide the molecular basis by which mutant p53 drives clonal expansion 
and preserves HSCs from chemotherapeutic agents (Lu, et al., 2012). Sox2 is a 
well-known pluripotency gene important for stem cell maintenance in embryonic 
stem cells (ESC) (Liu et al., 2013). Overexpression of crucial pluripotency genes 
has been shown to induce both pluripotency and self-renewal of ESCs 
(Takahashi et al., 2006). In addition, Hoffman and colleagues reported that 
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HDAC inhibition induces ex vivo expansion of cord blood CD34+ cells and this 
was due to upregulation of pluripotency genes, including Sox2 (Chaurasia et al., 
2014). This evidence suggested a novel role of pluripotency genes in regulating 
HSC expansion. Therefore, I speculated that mutant p53 driven clonal expansion 
of HSCs  may be, at least in part, due to increased levels of Sox2 in p53R248W/+ 
LSK cells. 
Collectively, I demonstrated that mutant p53 plays a gain-of-function role 
in HSCs by regulating genes or/and pathways important for HSC maintenance, 
leading to the development of pre-leukemic HSCs. These studies identify a novel 
GOF property for mutant p53 in changing genome-wide chromatin accessibility 
landscape. Moreover, understanding molecular mechanism by which mutant p53 
contributes to clonal expansion of HSCs may facilitate the development of novel 
therapeutic approaches for MDS patients with TP53 mutations. 
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CHAPTER SEVEN 
GOF mutant p53 interacts with EZH2 to drive pre-leukemic stem cell 
development 
Introduction 
Epigenetic modifiers are key regulators of HSC behavior and play critical 
roles in normal and malignant hematopoiesis (Shih, et al. 2012; Sun, et al. 2014; 
Beerman, et al. 2015). Thus, increased fitness of pre-leukemic HSCs could be 
due to dysregulation of epigenetic pathways. Indeed, genes involved in 
epigenetic regulations are most commonly mutated in pre-leukemic HSCs and 
clonal hematopoiesis, such as DNMT3A, TET2, ASXL1 (Genovese, et al 2014; 
Sperling, et al. 2017), highlighting the importance of epigenetic controls in the 
development of pre-leukemic HSCs. While TP53 is one of the top 5 genes that 
are commonly mutated in pre-leukemic HSCs and clonal hematopoiesis 
(Genovese, et al 2014), it is not clear whether mutant p53 interacts with 
epigenetic regulators to promote clonal expansion of pre-leukemic HSCs. 
Recently, GOF mutant p53 was found to bind the regulatory regions of 
several epigenetic regulatory genes, including MLL1, MLL2 and MOZ, and 
upregulate their expression, leading to cancer cell proliferation in breast cancer 
(Zhu, et al. 2015). MLL1 and MLL2 are SET family members of histone 
methyltransferases that mediate the tri-methylation of histone 3 at lysine 4 
(H3K4me3) (Krivtsov, et al. 2007; Rao, et al. 2015). MOZ is a histone 
acetyltransferase that mediates acetylation of histone 3 at lysine 9 (H3K9ac) 
(Sun, et al. 2015). Both H3K4me3 and H3K9ac are histone marks for 
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transcription activation (Krivtsov, et al. 2007; Sun, et al. 2015). The study linked 
the GOF mutant p53 with chromatin pathways in tumorigenesis. As the 
mechanisms of action for mutation p53 is dependent on cell context, the 
mechanism identified in transformed cancer cells may not be applicable to pre-
malignant adult stem cells. 
In Chapter 6, I demonstrated that mutant p53 altered the landscape of 
chromatin accessibility across the genome and changed the expression of genes 
important for HSC self-renewal. Given that epigenetic factors affect the 
accessibility of regulatory factors to chromatin during transcription initiation 
(Buenrostro, et al. 2013), it is likely that mutant p53 cooperates with epigenetic 
factors in regulating gene transcription. DAVID analysis of upregulated ATAC-
seq peaks in p53R248W/+ LSKs indicated that p53R248W functions as a 
transcriptional corepressor and involves in transcription repression related to 
RNA polymerase II (RNA Pol II) regulation (Figure 6.3.C). Polycomb Repressive 
Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2) repress 
transcription through inhibiting RNA Pol II (Bernstein, et al. 2006; Bracken et al., 
2009). Thus, I hypothesized that mutant p53 cooperates with epigenetic 
regulators to modulate genes or/and pathways essential for HSC 
maintenance. 
I first examined the mRNA levels of several epigenetic regulatory genes, 
including MLL1, MLL2, MOZ, and EZH2, in mutant HSCs. To determine which 
epigenetic pathways are altered in p53R248W/+ LSKs compared to p53+/+ LSKs, I 
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employed GSEA analysis to search epigenetic gene signatures in RNA-seq data 
I described in Chapter 6.  
Next, I performed flow cytometry analysis to evaluate the intensity of 
histone marks in HSCs. Moreover, I performed biochemical experiments to 
uncover potential mechanisms underlying epigenetic alterations in mutant HSCs. 
Finally, I employed ChIP-seq assays in p53+/+ and p53R248W/+ HSPCs in order to 
profile genome-wide epigenetic landscape in mutant HSPCs and understand how 
these alterations influence biological processes.  
The objective of this study was to explore how mutant p53 interacts with 
epigenetic pathways in regulating pre-leukemic HSC development, facilitating the 
development of therapeutic approaches for pre-leukemic HSCs harboring p53 
mutations. 
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Results 
1. GOF mutant p53 proteins enhance EZH2 activity in HSCs 
Recent studies from the Berger lab revealed that GOF mutant p53 
proteins increase the expression of several epigenetic factors, including MLL1, 
MLL2, and MOZ, in human breast cancer cells (Zhu et al., 2015). I therefore 
examined the expression of these epigenetic factors in p53+/+ and p53R248W/+ 
HSCs. As shown in Figure 7.1.A, the mRNA levels of Mll1, Mll2, and Moz were 
comparable in both groups. Interestingly, the expression of histone 
methyltransferase Ezh2 were modestly increased in p53R248W/+ HSCs compared 
to p53+/+ HSCs (Figure 7.1.A). Consistently, GESA analysis of RNA-seq data 
from p53+/+ and p53R248W/+ LSKs showed that the expression of Ezh2 targets 
were significantly downregulated in p53R248W/+ LSKs compared to p53+/+ LSKs 
(Figure 7.1.B), indicating that Ezh2 activity was enhanced in p53R248W/+ LSKs.  
EZH2 mediates methylation of histone H3K27me3, which is a repressive 
histone mark (Bracken et al., 2009). I examined the levels of H3K27me3 in p53+/+ 
and p53R248W/+ HSCs using ImageStream flow cytometry analysis. As shown in 
Figure 7.1.C, p53R248W/+ HSCs have increased H3K27me3 intensity compared to 
p53+/+ HSCs. Collectively, these findings suggest that GOF mutant p53 may 
enhance EZH2 activity in HSCs.  
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Figure 7.1 GOF mutant p53 enhances H3K27me3 in HSCs. 
(A) Quantitative RT-PCR analysis of Mll1, Mll2, Moz, and Ezh2 expression 
in p53+/+ and p53R248W/+ LSKs. n=3 biological replicates, **p<0.01. 
(B) GESA analysis shows negative enrichment of EZH2 signatures in 
p53R248W/+ LSKs compared to p53+/+ LSKs. 
(C) Median fluorescence intensity of H3K27me3 in p53+/+ and p53R248W/+ 
HSCs detected by ImageStream flow cytometry. n>=50 cells per group, 
***p<0.001. 
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2. Pharmacological inhibition of EZH2 activity decreased the replating 
potential of mutant HSPCs 
EZH2 is a critical regulator of HSCs (Kamminga, et al. 2006; Xie, et al. 
2014b; Mochizuki-Kashio, et al. 2017). While overexpression of EZH2 enhances 
HSC maintenance (Mochizuki-Kashio, et al. 2017), loss of EZH2 decreases the 
engraftment of HSCs in repopulation assays (Kamminga, et al. 2006). 
Remarkably, gain-of-function EZH2 mutations have been discovered in many 
hematological malignancies, including lymphoma, AML and multiple myeloma 
(Xie, et al. 2014b). Given that EZH2 inhibitors have been tested in clinical trials to 
treat cancer patients with high EHZ2 activity (Campbell, et al. 2015), I 
hypothesized that GOF mutant p53 depends on EZH2 activity in enhancing HSC 
self-renewal.  
To test this hypothesis, I plated 20,000 p53+/+ and p53R248W/+ BM cells in 
MethoCult GF M3234 culture with DMSO (0.01%) or EZH2 specific inhibitor 
EPZ011989 (3uM) and performed serial replating assays. EPZ011989 is a potent 
oral inhibitor which has been shown to inhibit EZH2-mediated H3K27me3 
(Campbell et al., 2015). I found that p53R248W/+ bone marrow cells showed 
enhanced colony formation compared to p53+/+ bone marrow cells in both and 
secondary Methocult culture (Figure 7.2). Interestingly, EZH2 inhibitor treatment 
decreased the colony formation of p53R248W/+ bone marrow cells back to p53+/+ 
cell level (Figure 7.2). Thus, the enhanced replating potential of BM cells 
expressing mutant p53 is dependent on EZH2 activity. 
 
139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Inhibiting EZH2 decreased replating potential of mutant 
HSPCs in vitro. 20x103 BM cells from p53+/+ and p53R248W/+ were seeded in 
methylcult treated with DMSO or EZH2 inhibitor (3µM). Primary colony 
number was counted at Day 7. Cells were harvested and seeded in new 
methylcult culture. Secondary colony number was counted at Day 7 after 
replating.  
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3. GOF mutant p53 proteins enhances H3K27me3 in genes important for 
HSC self-renewal  
ATAC-seq data from p53+/+ and p53R248W/+ LSK cells revealed that mutant 
p53 may act as a cofactor for EZH2-mediated transcriptional repression (Figure 
6.3.C). I hypothesized that mutant p53 enhances H3K27me3 through interacting 
with EZH2. To test this hypothesis, I expressed wild-type p53 or several mutant 
p53 together EZH2 in H1299 cells, a human lung cancer cell line with p53 
deletion (Wang et al., 1999). I then performed co-immunoprecipitation assays to 
see whether EZH2 was pulled down by p53 antibody. Interestingly, I found that 
several mutant p53 proteins, including p53R248W, p53R273H and p53R175H, 
displayed enhanced association with EZH2 compared to WT p53 (Figure 7.3).  
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Figure 7.3 Several mutant p53 proteins, but not wild type p53, interact 
with EZH2. H1299 cells were transfected with EZH2-HA, and wild type p53 or 
mutant p53 (R248W, R273H or R179H). Immunorecipatation was performed 
with p53 antibody and blot with HA antibody. 
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4. GOF mutant p53 proteins interact with EZH2  
To test whether GOF mutant p53 affects genome-wide H3K27me3 in 
HSPCs, we performed H3K27me3 ChIP-seq analysis in purified Lin-Kit+ cells 
from p53+/+ and p53R248W/+ mice.  GREAT pathway analysis was utilized to group 
genome-wide H3K27me3 occupancy into biological pathways. I found that 
p53R248W/+ cells showed non-overlapping H3K27me3 peaks in genes that 
positively regulate cell differentiation (Figure 7.4.A), whereas p53+/+ cells had 
non-overlapping H3K27me3 peaks in genes important for stem cell proliferation 
(Figure 7.4.B).           
Indeed, increased levels of H3K27me3 were found in genes regulating 
HSC differentiation and proliferation, including Gadd45g and Elf4/Mef 
(Thalheimer et al., 2014; Lacorazza et al., 2006; Liu et al., 2009b), in p53R248W/+ 
cells compared to p53+/+ cells (Figure 7.4.C). Consistently, both Gadd45g and 
Elf4 were significantly downregulated in p53R248W/+ LSKs compared to p53+/+ 
LSKs (Figure 7.4.D). Taken together, these data demonstrate that GOF mutant 
increases HSC competitive advantage through interacting with EZH2 and 
enhancing H3K27me3 in HSCs.  
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Figure 7.4 GOF mutant p53 regulates genes important for HSC self-
renewal through enhancing H3K27me3  
(A) GREAT pathway analysis of non-overlapping H3K27me3 peaks in 
p53R248W/+ Lin-Kit+ cells. 
(B) GREAT pathway analysis of non-overlapping H3K27me3 peaks in 
p53R248W/+ Lin-Kit+ cells. 
(C) H3K27me3 ChIP-seq analysis revealed the abundance and localization 
of H3K27me3 peaks at Gadd45g and Elf4 genes in p53+/+ and p53R248W/+ 
Lin-Kit+ cells.  
(D) Quantitative RT-PCR analysis of Gadd45g and Elf4 expression in 
p53+/+ and p53R248W/+ HSCs. n=3 biological replicates, *p<0.05, **p<0.01. 
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Conclusion and Discussion (Chapter Seven) 
Epigenetic modifications play critical roles in balancing HSC self-renewal 
with differentiation (Shih, et al. 2012; Sun, et al. 2014; Beerman, et al. 2015). 
Epigenetic regulatory genes are frequently mutated in aged healthy individuals 
with clonal hematopoiesis as well as in patients with hematological malignancies, 
including MDS and AML (Genovese, et al 2014; Sperling, et al. 2017), 
highlighting their importance in the evolution of hematological malignancies. In 
this study, I demonstrated that GOF mutant p53 proteins, but not wild-type p53, 
interact with histone methyltransferase EZH2 and enhance H3K27me3, leading 
to repression of negative regulators of HSC repopulating potential. 
Recent studies reported that GOF mutant p53 directly upregulated the 
expression of epigenetic regulatory genes, MLL1, MLL2, and MOZ, and 
increased level of H3K4me3 and H3K9ac, thereby promoting breast cancer cell 
proliferation (Zhu, et al. 2015). However, I proved that this was not the case in 
pre-leukemic HSCs with TP53 mutation. Instead, Ezh2, gene encoding a histone 
methyltransferase, was modestly upregulated in p53R248W/+ LSKs compared to 
p53+/+ LSKs. GSEA and flow cytometry analysis further confirmed that mutant 
p53 proteins enhanced EZH2 activity and increased H3K27me3 in HSCs. These 
results demonstrate that GOF mutant p53 function is context dependent. 
Mechanisms seen in cancer cells might not be applicable to pre-malignant stem 
cells. Further, mechanisms discovered in solid tumors may not function in 
hematological malignancies.  
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EZH2 is an important regulator of HSC self-renewal and B cell 
differentiation (Bracken et al., 2009). Overexpression of EZH2 enhances HSC 
maintenance (Mochizuki-Kashio, et al. 2017), whereas loss of EZH2 decreases 
the engraftment of HSCs in repopulation assays (Kamminga, et al. 2006). 
Notably, gain-of-function mutations on EZH2, have been identified in several 
hematological malignancies, including AML and MDS (Xie, et al. 2014b). 
Pharmacological inhibition of EZH2 reduces self-renewal of HSCs, therefore 
providing a novel therapeutic strategy to treat leukemia patients with high activity 
of EZH2 (Campbell, et al. 2015). To determine the functional impact of enhanced 
EZH2 activity on mutant HSCs, I performed serial replating assays of p53+/+ and 
p53R248W/+ bone marrows treated with EZH2 inhibitor. Remarkably, 
pharmacologic inhibition of EZH2 decreased the colony formation  of p53R248W/+ 
bone marrow cells back to WT level, suggesting that mutant p53 promotes HSC 
repopulating potential through enhanced EZH2 activity. These results provide 
functional links between mutant p53 and epigenetic regulators in pre-leukemic 
HSC development. Furthermore, to elucidate how mutant p53 enhances EZH2 
activity, I performed biochemistry studies and discovered that several mutant p53 
proteins, but not WT p53, interact with EZH2. These findings uncovered a novel 
mechanism of gain-of-function property of mutant p53 in regulating HSC function.  
Recently, genome-wide histone modification patterns have been 
extensively delineated by ChIP-seq assays in hematopoietic cells to understand 
the effect of epigenetic landscape changes on HSC function (Pepke, et al. 2009). 
We conducted ChIP-seq analysis of H3K27me3 in p53+/+ and p53R248W/+ HSPCs 
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and found that pathways involved in HSC self-renewal and differentiation were 
altered in mutant HSPCs. I also noticed that H3K27me3 levels in Gadd45g and 
MEF/ELF4 genes were increased in p53R248W/+ HSPCs compared to those of 
p53+/+ HSPCs. qPCR experiments and H3K27me3-ChIP assays further 
confirmed these findings.  
Growth arrest and DNA-damage-induced 45 gamma (Gadd45g) is one of 
the member of the Gadd45 family along with Gadd45a and Gadd45b. 
Gadd45 family proteins are known regulators in response to stress conditions 
and have been implicated in DNA damage repair, growth arrest, senescence and 
apoptosis. (Chen et al., 2014; Moskalev et al., 2012). Moreover, GADD45G is a 
tumor suppressor that is frequently silenced in many cancers (Liebermann et al., 
2011). Most importantly, GADD45G has been shown to accelerate terminal 
differentiation of HSCs, and deficiency of Gadd45g enhances the repopulation 
potential of LT-HSCs (Thalheimer et al., 2014). Interestingly, the expression of 
Gadd45g is increased in aged LT-HSCs, which have reduced reconstitution 
ability (Rossi et al., 2005), and knockdown of Gadd45g in aged HSCs enhances 
HSC self-renewal in vivo (Wang et al., 2012). All of these studies provided 
evidence proved that GADD45G is a negative regulator for HSC repopulating 
potential. In this study, I found that Gadd45g was downregulated in p53R248W/+ 
HSPCs through mutant p53 mediated H3K27me3. Therefore, I concluded that 
enhanced repopulating potential of mutant HSCs, was in part due to epigenetic 
silencing of Gadd45g in HSCs expressing mutant p53. I also predicted that 
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downregulation of Gadd45g contributed to the clonal expansion of mutant HSCs 
under genotoxic stresses. 
MEF, also known as ELF4, is a member of the ETS family of transcription 
factors. MEF/ELF4 is a key regulator in HSC quiescence and self-renewal 
(Lacorazza et al., 2006). Mef null LSK cells are more quiescent and thus 
resistant to chemotherapy and irradiation induced myelosuppression (Lacorazza 
et al., 2006). I found that mutant p53 mediated epigenetic downregulation of 
Mef/Elf4 expression through enhancing H3K27me3. I predicted that pre-leukemic 
HSC harboring mutant p53 downregulated Mef/Elf4 expression to escape from 
the cytotoxic effects of irradiation or chemotherapy. 
Collectively, I demonstrated that mutant p53 interacted with EZH2 and 
enhanced H3K27m3 in genes important for HSC functions. My findings that 
mutant p53 interacts with EZH2 to promote the repopulating potential of HSCs 
uncovered a novel gain-of-function mechanism of mutant p53 that contribute to 
pre-leukemic HSC development. Finally, my studies suggest that EZH2 might be 
an attractive therapeutic target for prevention and treatment of MDS patients with 
TP53 mutations. 
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CHAPTER EIGHT 
Summary and Future Directions 
Myelodysplastic syndrome (MDS) is a heterogeneous group of disease 
characterized by ineffective hematopoiesis, multi-lineage dysplasia and frequent 
progression to acute myeloid leukemia (AML) (Nimer, et al. 2008; Bejar et al., 
2011; Sperling, et al. 2017; Woll, et al. 2014). Cytopenia and transformation to 
AML attribute to the death of MDS patients (Nimer, et al. 2008; Bejar et al., 
2011). Mutations in tumor suppressor gene TP53 are present approximately in 
10% of MDS cases and are associated with dismal prognosis (Rücker, et al. 
2012; Volkert, et al. 2014; Welch, et al 2016; Sperling, et al. 2017；Chang, et al. 
2017;). Although progress has been made on MDS treatment, the clinical 
outcome of MDS patients with TP53 mutations is still very poor (Bejar et al., 
2011; Metzgeroth, et al. 2016; Sperling, et al. 2017). Bone marrow 
transplantation does not improve the outcomes of MDS patients with TP53 
mutations (Christopeit, et al. 2016; Lindsley, et al. 2017). Nevertheless, little is 
known regarding how these mutations contribute to the development of MDS. 
MDS is thought to arise from mutated HSCs (Nimer, et al. 2008; Cazzola 
et al., 2013; Sperling, et al. 2017). Accumulating studies indicate that the 
transformation event is initiated from the acquisition of pre-leukemic mutations 
driving the development of pre-leukemic HSCs, preceding the formation of fully 
transformed MDS stem cells (Corces-Zimmerman et al., 2014; Shlush et al., 
2014). Pre-leukemic HSCs have competitive advantage over normal HSCs 
without affecting hematopoietic differentiation (Corces-Zimmerman et al., 2014; 
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Shlush et al., 2014). While TP53 mutations and/or deletions are thought to be 
secondary events occurring during leukemic transformation (Harutyunyan et al., 
2011), acquired somatic GOF mutations in TP53 gene have been identified in the 
blood of aged healthy individuals as well as in patients with MDS (Bejar et al., 
2011; Genovese, et al. 2014; Jaiswal, et al. 2014), implying that TP53 mutations 
may be early events that initiate MDS.  
In this study, I characterized heterozygous GOF mutant p53 knock-in mice 
and discovered that p53R248W enhanced the repopulating potential of normal 
HSCs without affecting terminal differentiation. GOF mutant p53 promotes HSC 
expansion following genotoxic stress. Furthermore, GOF mutant p53 mice 
developed features consistent with human MDS during aging. Mechanistically, 
GOF mutant p53 increases the chromatin accessibility to genes important for 
HSC maintenance. Furthermore, GOF mutant p53 interacts with histone 
methyltransferase EZH2 and enhances histone H3 lysine 27 trimethylation 
(H3K27me3) in genes regulating HSC self-renewal and differentiation. Therefore, 
I demonstrated mutant p53 drive the development of pre-leukemic HSCs, but not 
leukemia stem cells (LSCs), predisposing aged mutant mice to the pathogenesis 
of MDS. My studies have uncovered mechanistic and functional links between 
GOF mutant p53 and epigenetic regulators in pre-leukemic HSC and MDS 
development.  
While TP53 mutations were identified in patients with MDS, p53-/- and 
p53R248W/R248W mice did not develop MDS (Song et al., 2007). As MDS is a 
disease of elderly and most p53-/- and p53R248W/R248W mice develop spontaneous 
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tumors within 3 to 6 months after birth (Song et al., 2007), it is possible that 
homozygous mutant p53 mice do not have enough time to develop MDS before 
death. Indeed, I found that 30% of aged heterozygous p53R248W/+ mice developed 
MDS manifested by leukopenia, anemia, and multi-lineage dysplasia in BM and 
PB. In addition, I found that MDS developed in mutant p53 mice was 
transplantable. Thus, I, for the first time, provided experimental evidence that a 
GOF mutant p53 drives MDS development in mice. Given that MDS patients with 
TP53 mutations are resistant to conventional chemotherapy (Bejar et al., 2011; 
Lindsley et al., 2013) and they cannot be cured by allogeneic bone marrow 
transplantation, the heterozygous mutant p53 mice developed MDS will provide a 
valuable tool to investigate MDS pathogenesis and test novel therapeutic agents 
that can target mutant p53. 
Notably, I observed that some p53R248W/+ mice developed lymphoma, 
sarcoma, and mixed disease with lymphoma and MDS. These findings were 
consistent with what have been reported in human cases with heterozygote TP53 
mutations. My findings suggest that pre-leukemic HSCs may exist in both 
myeloid and lymphoid malignancies, and diverse diseases may be initiated from 
the same recurrent mutation (Corces-Zimmerman, et al. 2014). My findings that 
p53R248W/+ mice developed different hematological malignancies highlighted the 
clinical importance for cancer prevention of pre-leukemic HSCs harboring TP53 
mutations.  
Additionally, my observations that mutant p53 affects terminal 
differentiation during ageing and aged mutant mice developed MDS raise the 
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question of how mutant p53 drives the pathogenesis of MDS. Given that TP53 
mutations cause genome instability (Brosh et al., 2009), whether p53 mutations 
interact or cooperate with genetic alterations to drive the pathogenesis of MDS is 
not clear. Therefore, further studies, such as whole genome sequencing and 
karyotyping, are needed to figure out what genetic alterations cooperating with 
mutant p53 in the pathogenesis of MDS.  
Clonal hematopoiesis is a process of cell competition (Jan et al., 2017), 
where normal HSCs are outcompeted by mutated HSCs. Studies on cell 
competition proposed that the competition event is cooperative, where losers 
promotes winners while winners suppress losers (Bondar and Medzhitov, 2010; 
Marusyk et al., 2010). In this study, I have elucidate the cell intrinsic mechanisms 
by which mutant p53 enhances repopulation potential and promotes clonal 
expansion of pre-leukemic HSCs. However, whether and how mutant HSCs 
cause negative impact on WT cells during clonal hematopoiesis still remain 
elusive. I predict that mutant HSCs may release inflammatory cytokines, causing 
apoptosis, senescence or pyroptosis of WT HSCs. Further investigation of how 
mutant HSCs suppress WT HSCs will improve our understanding of how rare 
clones become dominant and uncover novel gain-of-function mechanisms for 
mutant p53. Moreover, these findings may facilitate the development of 
therapeutic approaches that can improve WT HSC function during treatment.   
I demonstrated that mutant p53 maintains HSC function, leading to clonal 
expansion of HSCs in response to chemotherapy and irradiation treatment. As 
pre-leukemic HSCs may survive chemotherapy and serve as reservoirs for 
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disease (Corces-Zimmerman et al., 2014; Shlush et al., 2014), the presence of 
pre-leukemic HSC pool prevents conventional chemotherapy from achieving 
long-term remissions. Thus, there remains a critical need to develop novel 
therapeutic approaches that would be effective in targeting pre-leukemic HSCs 
and improve leukemia treatment.  
In Chapter Seven, I discovered that mutant p53 associated with EZH2 and 
enhanced H3K27me3 in genes important for HSC self-renewal and 
differentiation. Serial replating assays revealed that the enhanced replating 
potential of mutant HSCs was dependent on increased EZH2 activity. 
Considering that EZH2 interacts with GOF mutant p53 proteins, but not wild-type 
p53, our research has uncovered a novel mechanism by which GOF mutant p53 
modulates gene expression in HSCs. These findings indicates that EZH2 may be 
an attractive therapeutic target for pre-leukemic HSCs bearing TP53 mutations. 
In the future, whether pharmacologic inhibition or genetic knock-down of EZH2 
would decrease the repopulating potential of mutant HSCs in vivo and delays 
disease development need to be further examined. 
Moreover, I found that Gadd45g and MEF/ELF4 genes were 
downregulated in mutant HSCs due to enhanced H3K27me3 mediated by mutant 
p53. Gadd45g and MEF/ELF4 are negative regulator of HSC function 
(Thalheimer et al., 2014; Lacorazza et al., 2006; Liu et al., 2009b). 
Downregulation Gadd45g and MEF/ELF4 genes lead to resistance of HSCs to 
chemotherapy and irradiation (Thalheimer et al., 2014; Lacorazza et al., 2006). It 
is likely that pre-leukemic HSC harboring mutant p53 downregulated Gadd45g 
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and Mef/Elf4 expression in order to escape from the cytotoxic effects induced by 
irradiation or chemotherapy. Therefore, whether these targets contribute to the 
resistance of mutant p53 HSCs to conventional chemotherapy need to be 
determined.  
In summary, my studies will advance our understanding of the initiation 
and progression of MDS with TP53 mutations. Ultimately, delineating the effects 
of GOF mutant p53 and epigenetic regulators in pre-leukemic and MDS stem 
cells will likely identify novel targets in human MDS that may have therapeutic 
potential for eliminating drug-resistant pre-leukemic HSCs and MDS stem cells. 
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